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Abstract 
 
Gender, Reproductive, and Lifestyle Risk Factors Associated with Liver Disease Severity 
in Chronic Hepatitis B Infection 
Jing Sun 
      Hepatitis B is a common infectious disease worldwide. It is linked to a series of liver 
complications such as inflammation, fibrosis, cirrhosis, hepatocellular carcinoma, and 
liver-related death. It is well-established that males are more likely to develop severe 
forms of liver disease compared to female chronic hepatitis B (CHB) patients. The goal 
of this dissertation was to test three hypotheses that could potentially explain the gender 
difference between male and female liver disease severity in the hepatitis B infected 
population. The data in this dissertation is derived from the Haimen City cohort, 
established in 1992-93 in Haimen City, China. The goal of the first paper is to determine 
whether lifestyle and environmental related exposures could explain the gender 
differences in liver disease severity in the HBV infected population. The objective of the 
second paper is to better understand the impact of estrogen exposure by examining the 
effect of reproductive history on the severity of liver disease in CHB women. The third 
paper examines HBV viral load change over time among men and women and determines 
how this change may predict later liver disease. 
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CHAPTER I.  BACKGROUND AND LITERATURE REVIEW 
1. Background 
1.1. Hepatitis B Virus Infection and Liver Disease Progression Natural History 
      Hepatitis B is a common infectious disease worldwide. Based on a systematic review of 
global epidemiology studies of hepatitis B [1] and World Health Organization (WHO) data, over 
two billion people are currently infected with the hepatitis B virus (HBV) [2]. Additionally, there 
are about 600,000 people who die as a consequence of hepatitis B infections [2]. In some 
developing countries—China, for instance—hepatitis B is endemic. Approximately 100 million 
people are infected with the hepatitis B virus in China. Based on the data from the Ministry of 
Health of the People’s Republic of China, there were 1,093,335 and 1,060,582 new cases of 
hepatitis B in 2010 and 2011, respectively, while there were 637 and 689 people whose deaths 
were directly related to hepatitis B infection in those same years [3].  
      The hepatitis B virus (HBV) belongs to the hepadnavirus family. There are eight known 
genotypes (A to H) in human HBV [4]. Different genotypes have distinct geographic and ethnic 
distributions. Genotype A is common in Africa, Europe, and North America; genotype B and C 
are common in Asian populations; genotype D is mostly found in South Africa, India, parts of 
Europe, the Mediterranean basin, and Australia; genotype E is mostly found in Africa and South 
America; genotype E is mostly common in South America; genotype G is primarily found in 
Mexico; and genotype H is in central America [4]. Among all genotypes, genotypes C and D 
have been shown to be associated with the most severe form of liver disease [4].  
      The two major pathways of transmission of the virus include blood or body fluid transmission 
and maternal-fetal transmission. When people are infected with HBV, HBsAg (hepatitis B 
surface antigen) will present positive in a month, then HBeAg will present positive soon after that 
[5]. The first two months are usually identified as the incubation period of HBV. After the second 
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month, patients can develop HBc-antibodies in the blood, and such antibodies will last for the 
rest of the infection. HBs-antibodies are usually developed last, typically after 6 months of 
infection. Among all HBV biomarkers, hepatitis B E antigen (HBeAg), a precore protein, is 
translated from the HBV mRNA. The presence of precore protein expresses a nuclear transport 
signal for transport into the nucleus. HBeAg positive indicates a persistent infection in vivo, and 
it serves an immunoregulatory role in the natural infection by triggering various innate immune 
responses [4].  
      Hepatitis B viral infections can lead to asymptomatic and symptomatic acute hepatitis. After 
adult patients become infected, the immune systems of some patients can eliminate the viral 
infection through immune clearance (about 70% of adult in the population). Both asymptomatic 
and symptomatic patients have the possibility to develop chronic hepatitis B infections [6, 7]. 
Chronic hepatitis B (CHB) is most likely developed through maternal-neonatal transmission or 
through infection with the virus in early life (over 90% of chronic hepatitis B cases develop in 
childhood). Adults who are infected are most likely to develop acute hepatitis B, and about 1% of 
these cases develop into chronic hepatitis B infections [6]. The host’s innate and adaptive 
immune responses are the key factor that determines the outcome of HBV infections [7]. Patients 
who have lower HBV specific T cell responses will be more likely to develop chronic hepatitis B 
[7]. Even though the hepatitis B virus does not directly cause inflammation in liver cells, liver 
damage can result from HBV immune clearance. The immune system can actively clear the virus, 
but in the process of clearance it may induce inflammation and fibrosis, leading to cirrhosis [5-7]. 
About 30% of chronic HBV infections develop into cirrhosis. Cirrhosis can then progress to 
hepatocellular carcinomas (HCC) or liver failure [5, 7-9]. Beyond that, chronic HBV infection 
can also directly cause hepatocellular carcinomas (HCC).  
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      CHB patients have a high risk of developing HCC compared to the general population. Based 
on a longitudinal study done in Taiwan, HBV carriers are 223 times as likely to develop HCC 
compared to non-carriers [10]. In the Haimen study cohort, HBsAg positive participants associate 
with 18.8 (95% CI: 15.7-22.5) fold increase of risk of HCC mortality compare to those who were 
HBsAg negative in males, and 33.5 (95% CI: 17.1-65.5) fold increase in females.  HBV could 
cause HCC through two major pathways. First, HBV DNA could be integrated into host 
hepatocytes and inserted in or near proto-oncogenes or tumor suppressor genes. There are also 
indications that the HBx gene product could impair hepatocyte p53, a major tumor suppressor 
protein [4]. Second, HBV infection could also cause liver cancer in an indirect way. The CHB 
population often suffers various episodes of liver inflammation, and many among them develop 
fibrosis and cirrhosis in their life time. Among those who have developed cirrhosis, their 
hepatocytes are usually characterized by a loss of regenerative reserve, presence of fibrosis, 
activation of liver progenitor cells, and increased inflammatory signaling. The shortening of 
telomeres and the evolution of hepatocyte chromosomal instability could lead to development of 
HCC among those who have cirrhosis [4].     
      There are three major phases according to McMahon’s review paper on HBV natural history:  
the immune tolerant, immune active, and immune inactive phases [11]. Those in the immune 
tolerant phase typically received the disease from HBV infected mothers, and they have normal 
ALT, HBV DNA>200,000 IU/mL (>1 million copies), often above 107-8 IU/mL, and biopsies of 
their livers appear normal or only minimally inflamed and without fibrosis. Those in the immune 
active phase can typically be broken down into two types: HBeAg positive chronic hepatitis B 
patients will have elevated ALT levels and HBV DNA>20,000 IU/mL; anti-HBe positive chronic 
hepatitis B patients will usually show elevated ALT and HBV DNA >2000 IU/mL. In both cases, 
hepatic inflammation with or without fibrosis (identified through biopsy) may be present. 
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Patients in the immune inactive phase usually possess the following: 1) anti-HBe positive, 2) 
normal ALT levels, 3) HBV DNA<2000 IU/mL, 4) hepatic inflammation minimal or absent, 5) 
hepatic fibrosis may improve over time, and 6) HBsAg clearance may occur [11].  
      There are several scoring systems used for categorizing liver fibrosis samples taken from a 
liver biopsy, such as the Metavir (stages I–IV), the Child-Pugh score, the Ishak score (stages I–
V), and etc. al. One of the challenges in the field is that the scoring systems are not directly 
comparable to each other, and different studies use different systems. Basically, according to the 
Metavir Score (from the liver biopsy diagnosis on fibrosis), the severity of liver damage that 
accompanies chronic hepatitis B can be categorized (based on the degree of hepatic fibrosis) as 
none (inactive carrier), mild, moderate, or severe [5]. The five year survival rate for mild chronic 
hepatitis B is 97%, for moderate 86%, and for severe 55% [5]. Mild chronic hepatitis B can 
progress to the moderate level over time, and moderate can likewise progress to severe. The 
established factors that influence liver disease progression will be described in the later section.  
      Other than histology surveillance of liver fibrosis, HBV DNA replication is an important 
surrogate marker for HCC and liver disease progression [9, 12-14]. In patients with HBV chronic 
infections, HBV surface antigen HBsAg will remain detectable in blood. In most asymptomatic 
cases, HBV viral load will remain undetectable in the circulation, though it will remain present in 
the liver. When the infection is in the active HBV DNA replication stage, HBV viral load will 
significantly increase. This marker is used to identify the period in which the patient has the 
greatest level of infectivity and has the maximum liver damage [6, 14]. Previous studies [13, 14] 
indicated that there is a significant association between HBV viral load and the mortality and 
morbidity from hepatocellular carcinoma or chronic liver disease. In a Taiwanese prospective 
cohort study, serum HBV DNA showed a dose-response effect on HCC incidence [12]. The 
elevated serum HBV DNA level, greater than or equal to 1x104 copies/ml, is a strong risk factor 
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of HCC and liver cirrhosis regardless of the HBeAg status [12]. In the Haimen City Cohort study, 
HBV viral loads were classed in one of three categories:  undetected (<1.6x103 copies/ml), low 
viral load (1.6x103-9.9x104 copies/ml), or high viral load (≥1x105 copies/ml), respectively. For 
HBeAg-positive patients, the RRs for those who have low viral load and high viral load was 1.3 
and 7.5 times compared to the undetected viral load group [14].  
1.2. Established Risk Factors for Liver Disease and HCC 
      Besides the viral infection that can cause serious liver damage and disease, there are many 
other established risk factors that can contribute to impaired liver function. The following factors 
are the most commonly addressed in hepatitis etiology studies. 
1.2.1. Aging 
      The blood supply to the liver decreases every year in adults [8]. Since blood flow to the liver 
exchanges oxygen and nutrients with metabolic products and toxins, the reduced blood flow will 
reduce the liver’s detoxification and metabolic functions. In addition, since metabolism 
decreases, the amount of liver cells will also reduce dramatically after a certain age. One of the 
important immune cells, the Kupffer cell, reduces its phagocytic function by over 60% by age [5, 
6, 8].   Since Kupffer cells provide an important immune response to HBV virus clearance in the 
human body, aging can modify the effect of other risk factors in viral hepatitis. 
1.2.2. Alcohol 
      Excessive alcohol consumption can produce hepatic steatosis, alcoholic hepatitis, and 
alcoholic cirrhosis [5, 8]. In the U.S, alcohol is directly or indirectly associated with over 50% of 
liver disease related deaths [8]. In the short term, excess alcohol consumption will induce the 
formation of acetaldehyde, which disrupts liver microtubules and increases the liver 
NADH/NAD+ ratio. This change can induce liver cells to develop fatty degeneration, thus 
causing hepatic steatosis. The macrovesicular fatty change in the liver is a reversible change 
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when the patient has alcohol cessation. In a patient with sustained, long-term alcohol 
consumption, hepatocytes become swollen and necrotic with neutrophilic infiltration. In such 
cases, alcoholic hepatitis is developed. When the damaged liver develops micronodules and has 
irregularly shrunken scar tissue, patients would present with alcoholic cirrhosis [8]. This is a final 
and irreversible change in the liver.  
1.2.3. Smoking 
      Since the liver is the most important detoxification organ in the human body, the toxic 
chemicals in cigarette smoke can cause liver oxidative stress and eventually induce liver cell 
fibrosis [8]. In previous studies, smokers have shown a greater risk of developing hepatocellular 
carcinoma [15, 16].  Smokers may develop hepatocellular carcinoma due to the multiple 
mutagenic and carcinogenic components contained in tobacco. Also cigarettes can cause 
oxidative stress due to the generation of cytochrome P450E1-associated reactive oxygen species 
and depletion of endogenous antioxidants [17]. However, people with liver damage often lose 
their taste for cigarettes and quit smoking, so cross sectional studies would not detect an 
association.  
1.2.4. Diet 
      Previous studies indicated foods with the chemical flavacin (e.g. moldy rice, peanuts and 
corn), which is a carcinogenic chemical, can significantly increase the risk of liver cancer[8]. 
Some researchers indicated that aflatoxin contaminated food may inhibit the p53 gene in 
hepatocytes and induce HCC as result [18]. In previous studies, tea polyphenols, which are an 
important component in tea, were believed to have significant reverse effects on the development 
of HCC [19-22].  
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1.2.5. BMI 
      Obesity is a strong predictor of hepatic steatosis even in the patients with no history of 
alcohol use [8]. The initial mechanism responsible for causing hepatic steatosis differs from those 
involved in alcohol induced liver disease. The free fatty acids which are secreted from normal 
visceral adipose tissue can activate the intrinsic apoptosis pathway in liver cells, then damage 
normal liver cells that develop fatty degeneration. Besides hepatic steatosis, obesity is also an 
individual factor that induces hepatocellular carcinoma[8]. Previous studies have also shown that 
excess BMI is associated with liver disease progression in chronic hepatitis B and C patients [23, 
24]. In Lee’s study, BMI greater than or equal to 25 and an HBV DNA viral load over 2x105 are 
both strong predictors of liver fibrosis [24]. Previous studies suggest that high BMI is often found 
in liver disease patients because people with advanced liver disease often develop ascites, which 
increase body weight and girth not due to fat. Besides, chronic liver disease patients with 
cachexia have a counter causality effect on BMI. 
1.2.6. Drug Induced Liver Damage 
      Over 1,000 drugs have been proven to contribute to various levels of liver damage, at least in 
certain circumstances [25]. Drug-induced liver damage can cause acute liver failure. Commonly 
used drugs like acetaminophen, isoniazid, troglitazone, etc. al can mimic the liver damage of 
acute hepatitis; nitrogurantoin, methyldopa, diclofenac, etc. al can mimic chronic hepatitis liver 
disease; methotrexate can induce liver fibrosis and cirrhosis; valproic acid can induce symptoms 
of microvescular fatty liver disease [25].  
1.2.7. Genetic 
      There are many different genetic studies that have shown the link between genetic 
components and liver disease. For example, Sal-like protein 4 (SALL4), which is a marker of 
stem cells, has been shown to be strongly expressed in human HCC cells and hepatoblastoma 
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[26-28]. In addition, the DNA repair gene XRCC3 Thr241Met polymorphism has been 
considered a potential risk of hepatocellular carcinoma in previous research [29-31] .  
2. Statement of the Problem 
      Many previous studies have indicated that there is a substantial gender difference in 
hepatocellular carcinoma mortality and morbidity even after controlling for known risk factors 
such as viral infections, alcohol, smoking, and etc. al, although the reasons remain unclear [32-
34]. HBV infection has also been proven to associate with the progression of liver fibrosis and 
HCC among women [14, 35]. Some argue that lifetime estrogen exposure might be the protective 
factor that reduces liver damage and HCC risk [33]. Reproductive history (e.g. age at menarche, 
age at menopause, use of exogenous hormones, number of pregnancies) are useful indirect 
measurements of lifetime estrogen exposure, and no direct measurement exists. To my 
knowledge, the association between women’s reproductive history and the progression of liver 
disease among Hepatitis B infected women has not been studied. In this project, I have identified 
the association of women’s reproductive history and the severity of liver disease based on the 
prospective cohort study in Haimen, China (1993-2003). The information derived from this study 
can be useful in attempts to control liver disease progression in patients with a chronic HBV 
infection. 
3. Review of Literature 
3.1. Gender Difference in Liver Disease Severity and Mortality 
       There is a significant gender difference in cases of hepatocellular carcinoma (HCC), one of 
the serious clinical outcomes of hepatitis B chronic infections [32, 34, 36]. A systematic review 
focusing on HCC concluded that males had an incidence rate of liver cancer 2 to 4 times higher 
than females according to multiple studies conducted globally [36]. Based on previous studies, it 
is clear that males are more likely than females to develop and die from hepatocellular 
21 
 
carcinoma. In the eight year follow-up cohort study in Haimen City [32] it was found that males 
were at a much higher risk of HCC than females, and this result is independent of HBV patients’ 
infection status. Within the 90,000 person cohort, the crude gender differences for the HCC 
mortality cannot be neglected, even when taking into account the larger number of male 
participants (58,454) compared to female participants (25,340). In this cohort, only 77 women 
died from HCC versus 900 HCC deaths among men.  In addition, the female cohort showed a 
higher relative risk in association between HBsAg positive and HCC mortality in the multivariate 
model than that in the male cohort [32]. In the female cohort, the relative risk of HCC mortality 
associated with HBsAg positive is 33.5 (95% CI 17.1-65.5) after adjustments for age, history of 
acute hepatitis, family history of HCC, cigarette smoking, and alcohol drinking, while in the male 
cohort the RR is 18.8 (95% CI 15.7-22.5) after adjusting for the same covariates.  Cavazza, 
Caballeria, Floreani, and et. al indicated in their study done in Europe that males with primary 
biliary cirrhosis were 8.09 (95% CI: 1.93-33.8, p<0.01) times more likely to develop HCC than 
females [34] after controlling for age, smoking, alcohol, HBsAg positive, anti-HCV positive, and 
severe histological stage. 
      Chen et al observed a gender difference in hepatitis B viral load in the Haimen City Cohort 
[14]. In their article, they defined participants with HbsAg-positive with undetected viral loads as 
their baseline category, viral loads between 1.6x103-9.9x104 as “low,” and viral loads greater or 
equal to 1x105 as “high.” Using this method, 13.1% of females with HBV infection  were in the 
undetected HBV DNA group, while only 5.9% of males were in the same group (p<0.001) [14]. 
Again, these findings fit with those of earlier studies that suggested that males are more likely to 
develop severe symptoms of liver disease and progress into HCC than females. 
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3.2. Biological Association between Estrogen and Liver Disease Progression 
      The reasons for gender disparities in liver disease still remain unclear. There are several 
hypotheses that have been used to explain the gender differences regarding severe liver 
conditions in the general population and the HBV infected population. Some researchers believe 
that the gender differences of HCC mortality and morbidity between males and females are due 
to the fact that male’s lifestyle may have more exposure to HCC oncogenic factors, e.g., smoking 
and alcohol consumption [37]. However, the higher incidence of HCC in males than females can 
be also observed in animal studies, which eliminates the confounding factors associated with 
lifestyle [33, 38, 39]. These results implied that sex-specific hormones might contribute to the 
gender differences of HCC mortality or morbidity. Kemp’s study indicated that testicular 
feminized mutant mice, which lack functional androgen receptors, have a similar risk of drug 
induced HCC compared to female mice but much less than normal male mice [40]. In his study, 
testicular feminized mutant mice developed an average 0.7 liver tumors per animal, while normal 
males averaged 20 liver tumors per animal. Yu and Chen’s study conducted in Taiwan indicated 
that an elevated testosterone level in study participants was associated with an increased risk of 
hepatocellular carcinoma [41]. However, this hypothesis remains questionable and did not show 
statistically significant effects in animal studies [38, 39]. Even though this hypothesis can explain 
some gender differences in HCC morbidity and mortality, it does not provide enough evidence 
for HCC development and liver disease progression in the HBV infected population.  
      On the other hand, estrogen exposure has been associated with decreased risk of HCC in 
mice. In Agnew and Gardner’s study, daily administration of estrogen to mice of both genders 
showed decreased risk of HCC incidence compare to the control group [38]. In contrast, the daily 
administration of androgen did not show any increasing risk of HCC in the same study [38]. 
Naugler, et al observed the same gender disparity of liver cancer can also be seen in mice given 
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diethylnitrosamine (DEN, a chemical carcinogen) [33]. In addition, these researchers found that 
DEN can increase serum interleukin-6 (IL-6) concentration to a higher degree in males than in 
females. DEN exposure promoted the production of IL-6 in Kupffer cells on the Toll-like 
receptor protein MyD88. When this receptor is blocked, the risk of male mice developing HCC 
decreases.  Additionally, the removal of IL-6 could eliminate the gender differences in 
hepatocarcinogenesis in mice. The production of IL-6 in Kupffer cells might be a key factor 
inducing HCC. Estrogen, which can inhibit the secretion of IL-6 from Kuffer cells, might have 
mediated the inhibition of IL-6 production, thus protecting against HCC in females [33]. 
Shimizu, Ichiro, and Ito’s paper also suggested another potential role of estrogen in preventing 
hepatocytes from oxidative stress [42]. In this study, the researcher proved that the estradiol 
upregulated Bcl-2 expression in cultured rat hepatocytes undergoing oxidative stress. The 
overexpression of Bcl-2 is known to suppress lipid peroxidation and to prevent cell apoptosis. 
Besides, estradiol can also suppressing NADH/NADPH oxidase activity, which prevent 
hepatocyte from cell injury and cirrhosis. These findings suggested that estradiol protects 
hepatocytes from oxidative damage and increases cellular longevity [42].  
       A study done by Nakagawa et al. applied this hypothesis in a nested case control study of 
Hepatitis C infected patients in Japan [43]. The result showed that the hazard of HCC in higher 
serum IL-6 levels is 1.61 times (95% CI 1.12-2.31, p=0.01) per 1 log increase compared to lower 
IL-6 in females. However the trend was not present in the male cohort [43]. Also, in the bivariate 
analysis in this study, serum estradiol levels (<+20 pg/ml) was a significant risk factor for HCC 
development in female patients, with a hazard ratio of 2.5 (95% CI, 1.134-5.532, p=0.023). In the 
multivariate analysis section, the author claimed that the association between serum estradiol 
level and the risk of HCC development is not statistically significant after adjusting for the serum 
IL-6 level [43]. Based on Naugler’s hypothesis [33], estrogen will mediate the effect of IL-6 on 
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the risk of HCC development. It may be the reason why the effect of serum estradiol levels on the 
hazard of HCC was not statistically significant after adjusting for serum IL-6 in Nakagawa’s 
study [43].  
      Since we have evidence of a plausible association between estrogen exposure and 
hepatocarcinogenesis from animal experiments and cohort studies in chronic Hepatitis C, it will 
be very useful to carry out a study of the HBV infected population. The purpose of this 
dissertation is to identify the association between surrogates for lifetime estrogen exposure and 
liver disease severity among those with hepatitis B infection.  
3.3. Application of Reproductive History to Address Women’s Lifetime Estrogen Exposure 
       Lifetime estrogen exposure among women cannot be directly measured. In previous studies 
of breast cancer and women’s lifetime estrogen exposure, reproductive history (e.g. age at 
menarche, age at menopause, use of exogenous hormones, number of pregnancies, etc. al), has 
been widely used as a common proxy for lifetime estrogen exposure as well as other hormonal 
exposure [44-51]. According to Kelsey’s review paper, the use of reproductive histories in breast 
cancer studies had been based on previous studies that concluded the association between certain 
reproductive factors and the risk of breast cancer[51], and this combination of factors have been 
widely used to described the life-time estrogen exposure in many research fields since then. For 
instance, researchers tracked several reproductive and hormonal characteristics:  breastfeeding, 
parity, age of first full-term pregnancy above 30 years old, postmenopausal women with HER-2 
overexpression associated with the increasing risk of luminal breast cancer [44]. They also 
attempted to identify the association between breast cancer subtype and age of menarche, age of 
menopause, and oral contraceptive use, but did not find any significant association. A case-
control study [45] also applied reproductive history as a proxy measurement of lifetime estrogen 
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exposure. The researcher found that late menarche, late first delivery, and high parity were 
associated with increasing risk of premenopausal breast cancer [45].  
      The similar usage of reproductive history factors as a proxy measurements for life-time 
estrogen exposure have also been applied to many other diseases influenced by estrogen, e.g., 
cardiovascular disease, ovarian cancer, psychological disease, liver disease, and etc. al [52-59]. In 
general, reproductive history would be an appropriate indirect measurement to reveal the level of 
women’s lifetime estrogen exposure. Most studies have estimated the association between certain 
diseases and individual reproductive factors in their analysis. However, most reproductive factors 
are not independent from each other. For example, numbers of pregnancies correlate with number 
of live births, number of stillborn and etc. al. In Smith’s study, several reproductive factors are 
transformed by factor analysis as an estrogen exposure index [60]. In Hesson’s study, the 
researchers applied principal component analysis to transform multiple reproductive factors into 
an accumulative measurement (index of cumulative estrogen exposure) [59]. These studies gave 
me insightful examples that helped me deal with multiple correlated variables in this project.   
3.4. Association between the Risk of HCC and Reproductive History  
      Previous epidemiologic studies provided some evidence that there is an association between 
reproductive histories and the risk of liver cancer. The measurement of estrogen exposure is 
usually women’s reproductive history [61-63]. Tzonou’s study [62] evaluated the association 
between women’s parity status and risk of HCC. The study results indicated that the relative risk 
of HCC for nulliparous women was 0.6 times that of those who had one or two children 
(reference group). Women who had three or four children were 1.3 times more likely to develop 
HCC compared to the reference group, while women with five or more children were 1.7 times 
more likely to develop HCC. Another nested case-control study done in Sweden showed that 
parity status has a positive association with the risk of HCC[64]. In La Vecchia’s study, the 
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relative risk of HCC for parous vs. nulliparous women was 2.6 (95% CI: 1.2-5.8). And this risk 
presents a dose response effect: the relative risk of HCC for one child was 2.1, for 2 children was 
2.6, for 3 children was 3.2, and for 4 or more births was 3.5 (chi square trend = 6.49, p = 0.01) 
[65]. Hsing’s study [63] also showed a possible association between the number of live births and 
the risk of primary liver cancer. The risk for women who had had a live birth was 1.9 (95% CI 
0.9-4.0) compared to women who had never had a live birth. Although neither the dose-response 
effect nor the associations are statically significant. Because an increased number of live births 
are associated with higher estrogen exposure, the results were not consistent with the animal 
model study [33]. The same group also conducted an analysis to estimate the association between 
oral contraceptives and primary liver cancer in young women [61]. The investigator identified the 
use of oral contraceptives as a contributing factor relating to an increased risk of primary liver 
cancer (OR=1.6, 95%CI: 0.9-2.6), especially for long-term (≥10 years) users (OR=4.8, 95%Ci: 
1.7-14.0). Since oral contraceptives provide external estrogen, the results also did not agree with 
the animal study. However, due to the small sample size, there might not be enough power to 
detect the effects of lower parity and oral contraceptive use on HCC development. In addition, 
the previous studies were usually limited in their use of reproductive characteristics to such 
factors as parity status and oral contraceptive use, but they excluded other reproductive and 
hormonal characteristics. Most were also done in small sample studies focusing on HCC risk. 
They could not demonstrate the association between estrogen exposure and liver disease severity 
in a long term setting.  
      Previous studies provided evidence that women’s parity status was associated with the risk of 
liver cancer, though the associations showed an increased risk of HCC. To my knowledge, there 
are no previous studies that estimate the association between reproductive history and HBV viral 
load. The dissertation utilized the data from a ten-year follow-up cohort study in Haimen, China. 
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From the dataset, I have examined potential links between reproductive history and liver disease 
severity in the HBV infected population. This analysis will present a full picture of reproductive 
events that may indicate the influence of lifetime estrogen exposure on liver disease severity in 
Chinese women with chronic HBV infectious. 
4. Study Population and Data Collection 
4.1. Data Collection procedure 
      The data in this project is derived from a prospective cohort study conducted in Haimen City, 
China. The original cohort was assembled from all 35 townships in Haimen City between 
February 1992 and December 1993. The initial cohort included 58,545 men and 25,340 women. 
All participants completed a brief survey and donated a 9.0 ml blood sample by venipuncture. 
The baseline data collection did not include information on reproductive history or clinical 
classification of severity of liver disease. In 2003, the study team randomly selected 9 townships 
and invited 2,571 individuals who had tested as HBsAg positive at cohort entry in 1992-93 to 
participate in the screening exam to determine their current liver disease status. Of these, 1,863 
participants actually attended the exam. The reproductive histories and hormonal characteristics 
were collected at this point. Common risk factors for liver disease progression—for example age, 
smoking, alcohol use, prescription drugs use, family history of liver disease, etc. al—were 
measured. Liver disease severity was categorized as one of the following in the original cohort 
study: “normal”, “mild”, “moderate”, “severe”, “HCC”, and “undefined”. The undefined 
category consists of a small number for which data is missing in the original cohort and thus will 
be omitted in the analysis. After estimating the distribution of the outcome variable, I combined 
the mild and moderate liver disease as a new category, and severe liver disease and HCC as a 
new category. Serum HBV viral loads were measured in samples from study entry and at the time 
of the 2003 exam.  
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4.2. Inclusion and Exclusion Criteria 
      One thousand eight hundred and sixty three participants with HBsAg who participated in the 
screening exam in 2003 again were selected in this study. In this analysis, the participants with no 
confirmed HBsAg positive exams were removed. Patients with “undefined” liver disease severity 
might have lost one or more value in the process of calculating the CLD level. All participants 
with “undefined” liver condition will be recoded based upon all the criteria available in the data 
set. A missing data imputation will be applied in this process if necessary.  The liver disease 
severity scale is combined to three levels. Further inclusion and exclusion criteria will be 
presented in the basic characteristics tables in Appendix 2-1. 
4.3. Missing values 
      All outcome variables (liver disease severity) that are missing have been recoded based on 
patients’ physical examination, ultrasound results, and blood test results to improve the power of 
the analysis. In the original dataset, some variables, such as lifestyle exposures and reproductive 
history, also included missing values. The missing imputation can improve the internal validity 
and power of the analysis. The missingness of the variables were explored carefully in order to 
determine if it is missing completely at random or if it is informative missingness. I applied 
multiple imputation methods in the analysis in 3 aims [66].  
5. Specific Aims and Rationale for Analyses 
       The following three specific aims are developed based on my previous literature reviews and 
the availability of data from the ten-year-cohort study in Haimen, China. 
Aim 1: Determine whether lifestyle and environmental related exposures could explain the 
gender differences in liver disease severity in the CHB population.  
Aim 2:  Determine whether reproductive factors may account for some of the differences in liver 
disease severity seen in women with CHB. 
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Aim 3: Examine HBV viral load change over time among men and women and determine how 
this change may predict later liver disease. 
5.1. Aim 1: Determine whether lifestyle and environmental related exposures could explain 
the gender differences in liver disease severity in the CHB population  
      Previous studies have hypothesized that the gender difference in liver cancer among CHB 
might be due to lifestyle-related difference between males and females [37]. In Chen, et al.’s 
study, the results suggested that smoking and alcohol consumption are significantly associated 
with odds of liver cancer among male in a case-control study [37]. The researchers suggested that 
although sex hormones have been suggested as an explanation for the gender discrepancy, 
cigarette smoking and alcohol consumption might also have contribution to this difference. Also, 
as mentioned in the previous section, cigarette smoking and alcohol consumption are both 
established risk factors for liver damage. It is valuable to determine how much, if any, the 
lifestyle and environmental exposure could explain the gender difference in liver disease severity 
in CHB population. 
      The purpose of this aim is to identify the risk difference of severe liver disease among males 
and females due to lifestyle and environmental exposure. In a power analysis excluding the 
missing value on liver disease severity, there are 781 females and 1010 males in the sample. 
Based on the preliminary analysis, the proportion of those with liver conditions (CLD=2 or 3) 
among males is 49.31%, while the proportion with liver conditions (CLD=2 or 3) among females 
is 29.96%. If there is not any covariate effect (R squared is 0), after 5000 iterations of sampling 
with a sample size of 1791 (of which 44% are female and 56% are male), in order to achieve the 
desired power of at least 80% at a 0.05 significance level, the minimum detectable change in 
probability of abnormal liver condition comparing the male versus female group is 0.29 to 0.35. 
This change corresponds to a minimum detectable odds ratio from the gender effect in this 
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sample of 1.35. When the lifestyle and environmental index correlates slightly with gender (R 
square 0.3), the minimum detectable odds ratio from the gender effect with 80% power at a 0.05 
significant level is 1.45. When the R square of the correlation between gender and lifestyle index 
is 0.8, the minimum detectable odds ratio from the gender effect with 80% power at a 0.05 
significant level is 1.9. Figure 1-1 shows how the power of detecting the different effect size of 
gender changed based on the correlation between gender and lifestyle and environmental index. 
5.2. Aim 2: Determine whether reproductive factors may account for some of the 
differences in liver disease severity seen in women with CHB 
      Previous studies also proposed the hypothesis that sex hormones might play a big role in the 
gender difference in liver disease severity and HCC. Some have suggested that estrogen could 
suppresses the liver’s innate immune response and has a protective effect on liver disease 
progression in CHB patients [67].  Liu, et al.’s study provided evidence that estrogen receptor 
ERα expression was decreased among most female hepatocellular carcinoma patients [68]. Based 
on animal experiments, Naugler, et al. proved that ERα plays a role in inhibiting Kuffer cell’s 
interleukin 6 (IL-6) production in the liver and protects female mice against liver damage [33]. 
Since IL-6 significantly increases when liver disease is exacerbated and during clearance of 
HBeAg [69], the evidence suggests that estrogen could play an important role in protecting 
females against inflammation induced liver damage during the virus clearance process. As far as 
our knowledge, there is no study that has examined reproductive history and liver disease 
severity in CHB women. It is important to verify this hypothesis in a human population that 
carries HBV. 
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5.3. Aim 3: Examines HBV viral load change over time among men and women and 
determines how this change may predict later liver disease 
      Animal studies have suggested that androgen might impact on HBV mRNA transcription. 
Tian, et al. observed that androgen-stimulated androgen receptor (AR) increased HBV 
transcription [70]. They also identified two androgen response elements (ARE) located in HBV 
nucleotide (913-927 and 949-963) enhancer I. These ARE were available for binding in various 
HBV genotypes [70-72]. Therefore, high serum androgen in males could up-regulate HBV gene 
transcription and encourage high viral load in males [70-72]. Besides the androgen up-regulation 
effect on HBV mRNA transcription, some have also suggested that estrogen might have a down-
regulation effect on HBV mRNA transcription. Almog et al.’s research indicated that high dose 
estrogen treatments could reduce serum HBeAg level in immunocompromised male mice [73]. 
Both hypotheses have not be studied in the human population. It is important to verify these 
findings from animal studies in a human population. In addition, HBV viral load has been 
associated with increased risk of HCC and cirrhosis in previous studies of the CHB population 
[12, 14]. Since HBV vial load fluctuates over time, it is beneficial to observe general changes in 
the HBV viral load over time as well as how such changes will impact on liver disease severity in 
the CHB population.  
6. Protection to Human Subjects 
      This project is based on the Haimen, China cohort data. The initial cohort study was reviewed 
and approved by the Institutional Review Board of Fox Chase Cancer Center, the Medical Ethics 
Review Group of Haimen City, and the Ethics Review Committee of the School of Public Health 
of Fudan University. The information in the data is de-identified secondary data. Thus this 
dissertation falls under the exempt category of Human Subject Research. The usage of data does 
not conflict with others.        
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Figures 
Figure 1-1 Power of detecting odds ratio of gender effect on risk of abnormal liver disease 
condition by R square of gender with lifestyle and environmental index  
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CHAPTER II: CONTRIBUTION OF LIFESTYLE AND ENVIRONMENTAL 
EXPOSURES TO LIVER DISEASE SEVERITY IN CHRONIC HEPATITIS B 
INFECTION: OBSERVATIONS FROM THE HAIMEN CITY COHORT 
2.1. Abstract 
Background: Previous studies have noted significant gender difference in the risk of liver cancer 
among hepatitis B chronic infection patients. Some indicated that it may be due to lifestyle-
related differences. This paper aims to demonstrate how the effects of gender might be 
confounded by lifestyle and environmental related exposures. 
Methods: We retrieved a sample of 1863 participants from a prospective cohort in Haimen City, 
China in 2003. Liver disease severity was categorized as “normal”, “mild”, “moderate”, and 
“severe” based on clinical diagnosis. Lifestyle and environmental exposures were measured by 
questionnaires. We used factors that derived from factor analysis or individual variables to 
represent lifestyle and environmental exposures. We applied the cumulative logit models to 
estimate the effect of gender on liver disease severity and how it was impacted by lifestyle and 
environmental exposures.  
Results: Gender and HBeAg positive were independent risk factors for more severe liver disease. 
We observed an interaction between gender and HBeAg status. Compared with females with 
HBeAg negative, females with HBeAg positivewere 2.67 times as likely to have severe liver 
disease (95% CI: 1.61-4.43), males with HBeAg negative were 2.09 time as likely (95% CI: 1.65-
2.63), and males with HBeAg positive were 4.27 times as likely (95% CI: 2.85-6.40). Controlling 
for lifestyle and environmental exposures did not change these estimations.  
Conclusions: Males in the HBV infected population have an increased risk of liver disease 
severity. The effect of male gender on liver disease severity differs by HBeAg status. This gender 
effect is independent of lifestyle and environmental exposures. 
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2.2. Background 
      Hepatitis B infection is prevalent worldwide. Over 240 million people have chronic hepatitis 
B (HBV) infection [1, 2]. HBV chronic infection could lead to high risk of death from cirrhosis 
of liver and liver cancer [3]. Hepatitis B e antigen, which is an indication of HBV viral load 
replication, has been associated with severe liver disease condition and hepatocellular carcinoma 
(HCC) in previous studies [4, 5]. Significant gender difference in risk of HCC among hepatitis B 
chronic infection patients were observed in previous studies [6-8]. Males are more likely than 
females to develop and die from hepatocellular carcinoma. In the eight year follow-up cohort 
study in Haimen City [6], researchers found that males associated with 1.8-6.7 fold increase risk 
of HCC compare to female. Some have speculated that the gender discrepancy may be due to 
lifestyle-related differences [9], since previous epidemiologic studies have shown the effect of 
lifestyle-related exposure (e.g. alcohol consumption and smoking habits) increase the risk of 
hepatocellular carcinoma in hepatitis B infected patients [3, 10]. 
      The purpose of this study is to determine whether lifestyle and environmental related 
exposure could explain the gender differences in liver disease severity in the HBV infected 
population. We examined this effect by utilizing cross-sectional data derived from a long-term 
prospective study in HBV-infected Chinese adults from the Haimen City cohort. 
2.3. Methods 
Study Population 
      The data in this study is derived from a prospective cohort study established in 1992-93 in  
Haimen City, locate in the eastern province of Jiangsu in China [6]. Among the cohort, 2763 
participants had sufficient serum information available. During the 10 years follow-up time, there 
were 231 participants died from chronic liver disease. In 2003, the research team invited 2571 
surviving HBsAg-positive cohort members for evaluation of current liver disease status. Of these, 
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1863 (72.5%) participants attended the screening and evaluation. The initial cohort study was 
reviewed and approved by the Institutional Review Board of Fox Chase Cancer Center, 
Philadelphia, PA, USA, the Medical Ethics Review Group of Haimen City, China, and the Ethics 
Review Committee of the School of Public Health of Fudan University, Shanghai, China. 
Measurements 
       The details of data collection, laboratory methods, and diagnosis criteria were reported in 
previous published papers based on the same cohort [6, 11]. HBeAg status were assayed on 
stored samples collected in 2003. Liver disease severity in this cohort was categorized as: 
“normal”, “mild”, “moderate”, “severe”, and “HCC” [11]. Normal is identified as possessing no 
abnormalities on any test or exam except for HBV markers. Mild is identified as having abnormal 
ALT and/or AFP only. Individuals are classified as moderate due to physical findings or 
laboratory test results indicative of abnormality, but they did not meet the criteria for probable 
fibrosis/cirrhosis or HCC. Severe is identified as having at least two of the following: 1)Spider  
nevi,  scleral  icterus,  palmar  erythema,  ascites,  hepatomegaly,  or splenomegaly; 
2)Thrombocytopenia and/or prolonged (>2 seconds) prothrombin time; 3)Portal vein enlargement 
(>12 mm) on ultrasound.  HCC is identified by the presence of a mass (>2 cm) on ultrasound and 
AFP >400 ng/ml.  For the purpose of analysis in this current study, we have combined “severe” 
and “HCC” as severe liver disease.  
      Lifestyle and environmental exposure were collected through interview in 2003. Smoking 
habit information included: 1) ever smoked (defined as smoked more than 1 cigarette for more 
than half of a year); 2) age started smoking; 3) number of cigarettes per day. Alcohol 
consumption information included: 1) current alcohol drinking (defined as drinking three or more 
times per week over half a year); 2) previous alcohol drinking; 3) drinking start age; 4) types of 
alcohol consumed (alcohol contents over 40% classified as high, alcohol contents between 20%-
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40% classified as middle, and alcohol contents less than 20% classified as low); 5) alcohol 
consumption quantity per week (for this analysis, we classified it as ≤2500g per week and 
>2500g per week). Tea drinking information included: 1) ever frequent tea drinker (identified as 
drinking tea three or more times per week over half of a year); 2) age start drinking tea; 3) 
number of cups of tea per week; 4) types of tea drinking (green, black or jasmine). Drinking 
water information included: 1) current drinking water source; 2) ever drank well water; 3) years 
drank well water; 4) ever drank river/ditch water; 5) years drank river/ditch water. All lifestyle 
and environmental exposure have no or less than 2% of missing values. Missing values were 
imputed using multiple imputations [12]. Occupation and family history of HCC were also 
collected during interviews.  
Statistical Methods 
      We used SAS 9.3 for all statistical analyses. All statistical tests were two-sided. We applied 
cumulative logit regression models in the overall analysis. We tested the parallel regression 
assumption [13], and the gender effect on liver disease severity has satisfied the assumption. 
Some lifestyle and environmental exposures measured in the survey were correlated with each 
other, we developed four models using different methods to represent different features of 
lifestyle and environmental exposures variables. In the first model, only age, age quadratic term 
(age2), gender, HBeAg status, and HBeAg * gender interaction terms were entered the model. 
Lifestyle and environmental exposure variables were correlated to each other in our data. In order 
to reduce the dimension of lifestyle and environmental exposure variables, we applied factor 
analysis to represent all lifestyle and environmental exposure variables in model 2. All variables 
in model 1 and five factors produced in factor analysis (summarized in Table 1) had entered 
model 2. In model 3, we first fitted each individual lifestyle exposure variables (smoking, alcohol 
consumption, and tea drinking) into Model 1 and calculated the magnitude change of gender 
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effect on liver disease severity. Since none of the variables showed a gender effect magnitude 
change over 5%, we then selected the variables that had the highest magnitude changes related to 
smoking, and alcohol consumption entered the model 3. In model 4, we applied the same method 
to test all lifestyle variables (smoking, alcohol consumption and tea drinking) and environmental 
related (drinking water) variables. Again, none of the individual variable showed a magnitude 
change on gender effect over 5%. We then selected five binary variables that reflect the previous 
exposure of smoking, alcohol consumption, tea drinking, and drinking water entered the model 4. 
Beta coefficients, standard errors, and p-values for each intercept and covariate are reported for 
each model. Odds ratios (ORs) and 95% Confidence Intervals (95% CIs) for gender in each 
model were reported separately based on additional calculation.  
2.4. Results 
Basic characteristics of the Study Population 
      Table 2-1 presents the basic characteristics of the participants and their prevalence in each 
level of liver disease severity. There are total of 1863 participants in this study, all of them were 
infected with hepatitis B. Among all of the participants, 56.8% were classified as normal, 9.1% 
were classified as mild, 10.1% were classified as moderate, and 23.9% were classified as having 
severe liver disease.  The total mean age of the participants is 52.2±17.3, and the bivariate 
association between age and liver disease severity is statistically significant tested by ANOVA 
(P-value<0.01). Among 1863 participants, 56.4% were male, 43.6% were female. Males were 
more likely to have severe liver disease. Among those who had normal liver, only 48.5% were 
males, while among those who had mild, moderate and severe liver disease, over 66% were 
males (p-value<0.01).  
      There were 30.2% participants who reported ever smoking. The prevalence of ever smoking 
was higher in the moderate and severe liver disease categories compared to the normal and mild 
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categories (40.4% in moderate liver disease vs. 25.5% in normal liver condition, P-value<0.01). 
Among all participants, 68.1% were not regular drinker of alcohol, 3.9% previously but not 
currently drank alcohol, 28.0% were current alcohol drinker. The prevalence of past alcohol 
drinking was higher among those with more severe liver disease (P-value<0.01). Among those 
who ever drank alcohol, more than half started drinking by age of 20 (55.9%), and this proportion 
was even higher among those with severe liver disease (64.6%). About 47% of those who drank 
reported they consumed over 2500g alcohol per week. The bivariate association between alcohol 
quantity and liver disease severity was statistically significant (P-value for Fisher’s exact test was 
0.05). There were 98% of the participants who claimed that they had consumed river or ditch 
water before. Those who had not drank river/ditch water were more likely to had a severe liver 
disease condition (P-value for Fisher’s exact test <0.01).  
Unadjusted associations between Lifestyle and Environmental Exposures and Gender 
      In this study, multiple lifestyle and environment related exposures tested to be statistically 
significant associated with gender in bivariate analysis (detail showed in appendix 2-1). These 
variables included occupation, smoking (had ever smoked, smoking start age, quantity of 
smoking per day), alcohol consumption (drank alcohol previously, drinking start age, quantity of 
alcohol consumption per week), previous frequent tea drinker, drinking water (drank well water 
previously, and years drank river/ditch water before) all had a p-value less than or equal to 0.02 
in the Fisher’s exact test or Spearman correlation test.  
Variance and Covariance about LifeStyle and Environmental Exposures based on Factor 
Analysis 
       Factor analysis was performed using 28 variables that related to lifestyle and environmental 
exposure. We generated factors that represent the different dimensions of lifestyle and 
environmental exposures variables based on the variance and covariance matrix of these 
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variables. Figure 2-1 demonstrates the scree plots for cumulative and individual proportion of 
variances explained by each factor. We evaluated the Scree plots, variances explained by each 
factors, and the model fit when fitting different combination of factors in cumulative logit 
models. We then decided to retrieve five factors, which explained 63% of the variances of all 
lifestyle and environmental exposures, from the factor analysis. The results from Factor analysis 
and loading for all variables in each factor were presented in Table 2-2. Factor 1 (explained 
24.7% of the variance) mostly reflected variables related to smoking and alcohol consumption. 
Factor 2 (explained 14.7% of the variance) mostly reflected the variables related to tea drinking. 
Factor 3 (explained 8.6% of the variance) mostly reflected the variables related to drinking water. 
Factor 4 (explained 7.9% of the variance) mainly reflected the variable related to smoking. Factor 
5 (7.3% of the variance) mainly reflected the variables related to drinking water.  
Cumulative Logit Regression Models  
       Table 2-3 shows results from four cumulative logit models. Among four models, model 2 
had the lowest Akaike information criterion (AIC) of 4050.0. Age was an independent risk factor 
for liver disease severity across four models. Age-squared was included in the models because 
age does not linearly associate with prevalence of liver disease severity. Gender is also an 
independent risk factor for more severe liver disease.  
      HBeAg positivity was an independent risk factor for more severe liver disease condition. It 
appeared that there is an interaction between HBeAg status and gender in our study. Based on 
model 1, HBeAg-negative males had a stratum specific OR of 2.15 (95% CI: 1.77-2.61) in the 
cumulative risk of more severe liver disease compared to females. Among HBeAg-positives, the 
stratum specific OR for males was 1.65 (95%CI: 0.90-3.01). Table 2-4 and Figure 2-2 shows the 
ORs and 95% CIs of different combination of gender and HBeAg status by using HBeAg 
negative females as a common reference group. The highest risk group appeared to be males with 
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HBeAg positive status. The combine OR of male gender and HBeAg positive in risk for liver 
disease severity is 4.37 (95% CI: 2.97-6.44) without adjusting for confounders, and 4.27 (95% 
CI: 2.85-6.40) after adjusting for five lifestyle and environmental factors.  
      Among all lifestyle and environmental exposures examined, ever drinking alcohol regularly 
was an independent risk factor for more severe liver disease in both model 3 and 4. In addition, 
the drinking of river/ditch water appeared to be a protective factor. Factor 3 in model 2, which 
mostly reflect drinking river/ditch water, appeared to be statistical significant (P-value<0.01). 
Ever drank river/ditch water was also statistically significant as a main effect in model 4 (P-
value=0.02). However, the magnitude of the effect of gender on liver disease severity did not 
change over 5% after adjusting for lifestyle and environmental exposures in model 2-4 compared 
to model 1 (Table 2-4). 
2.5. Discussion 
       HBeAg positive and male gender are independent risk factors for more severe liver disease 
condition. We detected interaction effect between gender and HBeAg status. In HBeAg-negative 
participants, males were approximately 2.15 times (based on model 1) as likely to have more 
severe liver disease compared to females, while in HBeAg positive participants, males were 
approximately 1.65 times as likely to have more severe liver disease compared to females. 
HBeAg positivity reduced the magnitude of the protective effect of female gender, independent 
of the lifestyle and environmental variables. As far as our knowledge, this difference has not been 
discussed in previous literature. The effect of gender on liver disease severity only changed 
slightly after controlling for lifestyle and environmental exposures, suggesting that the major 
explanation for the gender difference is due to endogenous exposures (e.g. hormonal differences) 
or genetic differences rather than lifestyle or environmental exposures.  
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      Most lifestyle and environmental exposures appeared to have bivariate association with liver 
disease severity (Table 2-1) and with gender (Appendix 2-1) in our study.  Current or previous 
smoking was associated with increased risk of severe liver disease in this population, which 
consistent with previous studies [14, 15]. The potential mechanism that causes smokers to 
develop hepatocellular carcinoma might be due to the multiple mutagenic and carcinogenic 
components contained in tobacco. Also, cigarettes can cause oxidative stress due to the 
generation of cytochrome P450E1-associated reactive oxygen species and depletion of 
endogenous antioxidants [16]. Males were more likely to smoke in our study (52.5% of males 
have ever smoked and 1.35% of females have ever smoked, P-value<0.01).  
      Alcohol consumption was an independent risk factor for liver disease severity in our study. 
Our results are consistent with previous studies that show excessive alcohol consumption can 
produce hepatic steatosis, alcoholic hepatitis, and alcoholic cirrhosis [17, 18].  In a study done by 
Ohishi et. al, alcohol consumption was associated with an approximately 4 times increased risk of 
HCC after adjusting for hepatitis B or hepatitis C infection [10]. Excess alcohol consumption will 
induce acetaldehyde formation, which disrupts liver microtubules and increase the liver 
NADH/NAD+ ratio. This change can induce liver cells to develop fatty degeneration, thus 
causing hepatic steatosis [18]. In our particular population, alcohol consumption also showed a 
bivariate association with gender. Females were less likely to have ever been a frequent alcohol 
drinker (89.2% of females vs. 51.9% of males never been frequent drinker in their life, P-
value<0.01).      
      We detected an independent effect of drinking water on liver disease severity in our 
population. Su, et al.’s study had mentioned the association of drinking water in China and HCC 
[19]. However further studies did not observe this association, and there were no sufficient 
biological mechanism could explain this effect. On the other hand, we observed drinking ditch 
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water were more common in the more rural townships in this population, which means drinking 
ditch water might be a surrogate marker for rural resident. We believe, this result might due to 
unmeasured confounding effect on socioeconomic status in the population.   
      The gender effect was not removed or modified by adjusting for lifestyle and environmental 
exposures, regardless of the association between lifestyle and environmental exposures and liver 
disease, and the association between lifestyle and environmental exposures and gender in our 
population. Based on the results from our multiple models analysis, our study does not support 
the hypothesis that lifestyle and environmental exposures are the key factor that drove the gender 
disparities in liver disease condition in the HBV infected population.  
      Other researchers has indicated that sex-specific hormones might contribute to the gender 
differences of HCC mortality or morbidity. Estrogen exposure has been associated with 
decreased risk of HCC in mice. In Agnew and Gardner’s study, daily administration of estrogen 
to mice of both genders showed decreased risk of HCC incidence compare to the control group 
[20]. In contrast, the daily administration of androgen did not show any increasing risk of HCC in 
the same study [20]. Further epidemiological studies in the human population are needed to 
support this hypothesis. On the other hand, Kemp’s study indicated that testicular feminized 
mutant mice, which lack functional androgen receptors, have a similar risk of drug induced HCC 
compared to female mice but much less than normal male mice [21]. In his study, testicular 
feminized mutant mice developed an average 0.7 liver tumors per animal, while normal males 
averaged 20 liver tumors per animal. Yu and Chen’s study conducted in Taiwan indicated that an 
elevated testosterone level in study participants was associated with an increased risk of 
hepatocellular carcinoma [22]. However, evidence for this has been mixed did not result in 
statistically significant effects in animal studies [20, 23]. Even though this hypothesis can explain 
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some gender differences in HCC morbidity and mortality, it does not provide enough evidence 
for HCC development and liver disease progression in the HBV infected population.  
      There were some limitations in our study. First, although the subjects were recruited from a 
prospective cohort study, lifestyle and environmental exposures were measured cross-sectionally 
at the time of the liver disease examination. Second, the measurements of lifestyle and 
environmental related exposures were only collected in certain questions in our study. We might 
miss other potential lifestyle and environmental related exposures that could be unmeasured 
confounder. However, we have tried several statistics approaches to represent the different 
features of these variables, the estimation on how lifestyle and environmental exposure impact on 
the association between gender and liver disease severity is not likely to change even if there are 
more measurements available. Third, the questionnaire-based exposure ascertainment is 
susceptible to information bias.  Fourth, people with chronic liver damage often lose their taste or 
smell [24]. They might quit smoking and alcohol due to loss of taste to alcohol and cigarette, so 
cross sectional studies might not be able detect the strong effect of smoking and alcohol even 
though our study asked about both past and present consumption. Future studies on lifestyle and 
environmental exposures related associations in a cohort study design are needed to verify our 
findings. 
2.6. Conclusion 
      Based on our observations, male gender increases risk of liver disease severity in the HBV 
infected population. The effect of male gender on liver disease severity is different by HBeAg 
status. Our results showed that this gender effect is independent of lifestyle and environmental 
exposures using either factor analysis or controlling for individual variables in a cumulative logit 
model.   
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Tables and figures 
Table 2-1. Characteristics and liver disease severity among participants in Haimen City Cohort in 2003 
Variable  Total  Liver Disease Severity P value  
P value stratified by 
gendera 
 (n = 1863) 
Normal  
(n = 1059) 
Mild  
(n = 170) 
Moderate 
(n=188) 
Severe 
(n=446)  
Male Female 
Demographic 
Age  52.2±17.3 52.9±17.9 50.7±15.6 50.9±16.1 51.8±16.7 <0.01 
 
0.01 
 
0.02 
Gender (%)      <0.01 - - 
Male 1051 (56.4) 512 (48.4) 113 (66.5) 127 (67.6) 299 (67.0)    
Female 812 (43.6) 547 (51.7) 57 (33.5) 61 (32.5) 147 (33.0)    
Occupation (%)      0.17 0.24 0.15 
       Peasant 1450 (77.8) 830 (78.4) 134 (78.8) 134 (71.3) 352 (78.9)    
        Non-peasant 413 (22.2) 229 (21.6) 36 (21.2) 54 (28.7) 94 (21.1)     
Smoking         
Ever Smoked (%)      <0.01 0.54 0.07 
        Yes 563 (30.2) 270 (25.5) 59 (34.7) 76 (40.4) 158 (35.4)    
         No 1300 (69.8) 789 (74.5) 111 (65.3) 112 (59.6) 288 (64.6)    
Smoking start age 
(N=563) 22.4±10.4 22.4±10.4 22.9±12.9 23.0±11.5 22.1±8.7 0.91 
 
0.96 
 
0.14 
Cigarette per day 
(N=563) 15.3±14.8 15.1±13.8 15.7±14.5 16.0±15.7 15.2±16.1 0.70 
 
0.62 
 
0.59 
Alcohol         
Alcohol drinker 
(%)      <0.01 
 
<0.01 
 
0.19 
Never regular 
drinker 1269 (68.1) 748 (70.6) 122 (71.8) 111 (59.0) 288 (64.6)  
  
Previous but not 
current drinker   73 (3.9) 32 (3.0) 6 (3.5) 6 (3.2) 29 (6.5)  
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Current drinker 521 (28.0) 279 (26.4) 42 (24.7) 71 (37.8) 129 (28.9)    
Drinking start age 
(N=594) 22.7±13.4 23.5±15.7 22.0±11.3 22.5±9.7 21.6±9.6 0.055 
 
0.49 
 
0.19 
Start age≤20 (%) 332 (55.9) 165 (53.1) 29 (60.4) 36 (46.8) 102 (64.6) <0.03 0.16 0.16 
Start age>20 262 (44.1) 146 (47.0) 19 (39.6) 41 (53.3) 56 (35.4)    
Alcohol spirit (%) 
(N=594)      0.35 
 
 
0.56 
 
 
0.43 
High 190 (32.0) 91 (29.6) 22 (45.8) 24 (31.2) 53 (34.0)    
Middle 133 (22.4) 70 (22.8) 7 (14.6) 17 (22.1) 39 (25.0)    
Low 265 (44.6) 146 (47.6) 19 (39.6) 36 (46.8) 64 (41.0)    
Quantity per week 
(*50g) (N=594) 64.3±113.4 
61.3±105.
1 52.5±99.8 
83.7±146.
9 64.5±111.4 0.04 
  
≤2500g per week 314 (52.9) 171 (55.0) 32 (66.7) 34 (44.2) 77 (48.7) 0.05 0.15 0.02 
>2500g per week 280 (47.1) 140 (45.0) 16 (33.3) 43 (55.8) 81 (51.3)    
Drink tea         
Drinking tea (%)      0.06 0.38 0.55 
Yes 139 (7.5) 68 (6.4) 16 (9.4) 22 (11.7) 33 (7.4)    
No 1724 (92.5) 991 (93.6) 154 (90.6) 166 (88.3) 413 (92.6)    
Age start drinking 
tea (N=139) 29.9±23.9 30.7±25.0 28.1±21.0 31.1±25.9 28.2±21.9 0.84 
 
0.89 
 
0.87 
Cups of tea per 
week 11.1±20.6 10.5±15.0 14.8±38.3 10.6±   
  
    18.2 11.1±20.5 0.80 0.71 0.14 
Types of tea      0.66 0.87 0.84 
Green 108 (77.7) 48 (70.6) 13 (81.3) 19 (86.4) 28 (84.9)    
Black 24 (17.3) 16 (23.5) 2 (12.5) 3 (13.6) 3 (9.1)    
Jasmine 5 (3.6) 3 (4.4) 1 (6.3) 0 1 (3.0)    
Drinking water            
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Current drinking 
water (%)       0.33 
 
0.72 
 
<0.01 
tap 1844 (99.0) 
1051 
(99.2) 167 (98.2) 185 (98.4) 441 (98.9)   
  
well 19 (1.0) 8 (0.8) 3 (1.8) 3 (1.6) 5 (1.1)     
Drank well water 
before (%)      0.91 
 
1.0 
 
0.21 
Yes 1445 (77.6) 816 (77.1) 133 (78.2) 145 (77.1) 351 (78.7)    
No 418 (22.4) 243 (23.0) 37 (21.8) 43 (22.9) 95 (21.3)    
Years drank well 
water (N=1445) 10.2±14.9 9.7±13.1 10.0±13.2 10.6±17.5 11.2±17.9 0.25 
 
1.0 
 
0.21 
Drank rive/ditch 
water before (%)      <0.01 
 
0.06 
 
0.11 
Yes 1826 (98.0) 
1047 
(98.9) 166 (97.7) 183 (86.2) 430 (96.3)  
  
No 36 (1.9) 12 (1.1) 3 (1.8) 5 (2.7) 16 (3.6)    
Years drank 
river/ditch water 
before (N=1826) 31.8±21.8 32.6±22.1 29.9±21.1 30.1±21.1 31.2±21.3 <0.01 
 
 
0.02 
 
 
0.38 
Family history of 
liver cancer (%)      0.04 
 
0.34 
 
0.09 
Yes 337 (18.1) 189 (17.9) 27 (15.9) 24 (12.8) 97 (21.8)    
No 1526 (81.9) 870 (82.2) 143 (84.1) 164 (87.2) 349 (78.3)    
 
Categorical variables were presented as number of subjects (row percentage) and tested by Fisher’s exact test. For numeric variables, the variables with normal distribution were expressed as mean ± SD and 
tested by independent samples Wilcoxon-Mann-Whitney test.  
a: In this column, all variables were analyzed in stratification by gender. All test were consisted with the analysis without stratification by gender.  
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Table 2-2. Lifestyle and environmental factors explained by loading of variables from factor analysis 
      Factor1 Factor2 Factor3 Factor4 Factor5 
Ever Smoker 0.62556 0.09444 -0.12134 -0.62358 0.28530 
Cigarettes per day 0.60960 0.05639 -0.10188 -0.59910 0.25977 
Smoking start age -0.60371 -0.01515 0.19765 0.65794 -0.18795 
Ever alcohol drinker  0.87893 0.36091 0.02742 0.20065 -0.10444 
Drinking start age -0.83303 -0.26256 0.06921 -0.09145 0.16074 
Age stop drinking alcohol 0.17633 0.10459 -0.07464 -0.10195 0.03582 
Quantity of drinking alcohol per week 0.69191 0.28003 0.05864 0.23118 -0.12105 
Current alcohol drinker 0.83365 0.33041 0.05838 0.23769 -0.11101 
High alcohol spirit drinker 0.43164 0.10168 -0.03141 -0.16932 0.08249 
Middle alcohol spirit drinker 0.33733 0.18746 0.01193 0.20865 0.03180 
Low alcohol spirit drinker 0.54614 0.25037 0.05937 0.27246 -0.23754 
Not regular alcohol drinker -0.87840 -0.35823 -0.03078 -0.21010 0.10719 
Ever tea drinker 0.48049 -0.81826 0.19425 0.11943 0.04564 
Age start drink tea -0.32648 0.62074 0.04980 0.07330 0.15011 
Cups of tea per day 0.39848 -0.66219 0.21023 0.04511 0.06366 
Not tea drinker -0.48032 0.81876 -0.19222 -0.12113 -0.04396 
Green tea drinker 0.43816 -0.73487 0.14619 0.12164 0.06739 
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Black tea drinker 0.15834 -0.32102 0.10963 0.01793 -0.03627 
Jesmine tea drinker 0.09903 -0.11169 0.07048 0.02262 -0.00360 
Ever drank well water -0.10330 -0.13612 -0.42731 0.00428 -0.40341 
Current well water drinker -0.10175 0.11226 0.69263 -0.40869 -0.56654 
Year drank well water 0.00151 -0.21422 -0.58152 -0.04508 -0.50125 
Ever drank river/ditch water -0.11909 0.17276 0.39559 0.07426 0.36506 
Year drank river/ditch water -0.06343 0.28672 0.50281 0.19890 0.51422 
Current river/ditch water drinker 0.10175 -0.11226 -0.69263 0.40869 0.56654 
The loading coefficient in bold showed in the table indicated the loading is greater than 0.45 or less than -0.45 
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Table 2-3. Cumulative logit regression model of liver disease severity and risk factors 
Variable  
Model 1 
AIC: 4054.0 
Model 2 
AIC: 4050.0 
Model 3 
AIC: 4056.8 
Model 4 
AIC: 4052.2 
 β (SE) P value β (SE) P value β (SE) P value β (SE) P value 
Intercept (severe) -4.77 (1.55) <0.01 -5.39 (1.57) <0.01 -4.64 (1.59) <0.01 -3.94 (1.67) 0.02 
Intercept (moderate) -4.26 (1.54) <0.01 -4.87 (1.57) <0.01 -4.13 (1.59) <0.01 -3.43 (1.67) 0.04 
Intercept (mild) -3.85 (1.54) 0.01 -4.46 (1.57) <0.01 -3.72 (1.59) 0.02 -3.02 (1.67) 0.07 
Age  0.14 (0.06) 0.02 0.15 <0.01 0.14 (0.06) 0.02 0.15 (0.06) 0.01 
Age*Age 
-0.00145 
(0.0005) 
<0.01 
-0.0015 <0.01 
-0.0015 
(.0005) <0.01 -0.002 (0.0005) 
<0.01 
Gender    <0.01  <0.01  <0.01 
Female 0  0  0  0  
Male 0.77 (0.1) <0.01 0.74 (0.12) <0.01 0.75 (0.12)  0.76 (0.12)  
HBeAg         
Positive 0.99 (0.26) <0.01 0.98 (0.26) <0.01 0.98 (0.26) <0.01 0.96 (0.26) <0.01 
Negative 0  0  0  0  
HBeAg*Gender -0.28 (0.32) 0.38 -0.27 (0.32) 0.41 -0.29 (0.32) 0.37 -0.27 (0.32) 0.40 
Factor 1   0.02 (0.05) 0.70     
Factor 2   -0.04 (0.05) 0.34     
Factor 3   -0.14 (0.05) <0.01     
Factor 4   -0.05 (0.05) 0.24     
Factor 5   -0.08 (0.05) 0.07     
Smoking         
Ever Smoked        0.63 
        Yes     0.004 (0.2) 0.99 0.06 (0.12)  
         No     0  0  
Cigarette per day (N=563)     0.005 (0.01) 0.67   
Alcohol         
Alcohol drinker         
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Never drinker     0  0  
Previous but not current 
drinker   
 
  0.41 (0.25) 0.11 0.47 (0.23) 
 
0.04 
Current drinker     -0.18 (0.15) 0.22 -0.09 (0.11) 0.42 
Drinking start age         
Start age≤20     0 0.40   
Start age>20     -0.14 (0.16)    
Drank Tea         
Yes       -0.02 (0.17) 0.91 
No       0  
Ever drank well water         
Yes       0.15 (0.11) 0.19 
No       0  
Ever drank river/ditch 
water  
 
     
 
Yes       -0.72 (0.31) 0.02 
No       0  
SE: standard error 
Model 1: age age*age gender HBeAg  gender*HBeAg  
Model 2: all variables from Model 1 and factor1-5 from factor analysis 
Model 3: all variables from Model 1 and individual variables (ever smoked, cigarette per day, ever drank alcohol, age start drinking alcohol) 
Model 4: all variables from Model 1 and individual variables (ever smoked, ever drank alcohol, ever drank tea, ever drank well water, ever drank 
river/ditch water)
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Table 2-4. Association between liver disease condition and gender by HBeAg status 
 Model 1  OR 
(95% CI) 
Model 2  OR 
(95% CI) 
Model 3  OR 
(95% CI) 
Model 4  OR 
(95% CI) 
HBeAg- female 1 1 1 1 
male 2.15 (1.77-2.61) 2.09 (1.65-2.63)  2.11 (1.67-2.67) 2.13 (1.69-2.70) 
HBeAg+ female 2.70 (1.63-4.48) 2.67 (1.61-4.43) 2.66 (1.60-4.41) 2.62 (1.58-4.36) 
male 4.37 (2.97-6.44) 4.27 (2.85-6.40) 4.21 (2.80-6.32) 4.27 (2.84-6.41) 
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Figure 2-1. Cumulative and individual proportion of variance explained by each lifestyle and 
environmental factor in factor analysis. 
 
Statistics are shown in Table 2-2. 
 
 
Figure 2-2. Association between severe liver disease and gender by HBeAg status 
 
Odds ratios and 95% confidence intervals are based on Model 2. Statistics are shown in Table 2-3. 
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Appendices 
Appendix 2-1. The Relationship between Lifestyle and Environmental Factors and Gender. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable   Gender P value  
 
 Male 
N=1051 
Female 
N=812  
Smoking     
Ever Smoked (%)    <.01 
        Yes 563 (30.2) 552 (52.5) 11 (1.4)  
         No 1300 (69.8) 499 (47.5) 801 (98.7)  
Smoking start age 
(N=563) 22.4±10.4 
 
22.2±4.9 
 
33.4±12.3 <.01 
Cigarette per day 
(N=563) 15.3±14.8 
 
15.4±7.5 
 
10.4±5.8 .02 
Alcohol     
Alcohol drinker 
(%)  
  
<.01 
Never frequent 
drinker 1269 (68.1) 
545 (51.9) 724 (89.2) 
 
Previous but not 
current drinker   73 (3.9) 
 
56 (5.3) 
 
17 (2.1)  
Current drinker 521 (28.0) 450 (42.8) 71 (8.7)  
Drinking start age 
(N=594)  
 
 
 
 
Start age≤20 (%) 332 (55.9) 306 (60.5) 26 (29.6) <.01 
Start age>20 262 (44.1) 200 (39.5) 62 (70.5)  
Alcohol spirit (%) 
(N=594)  
  
.24 
High 190 (32.0) 164 (32.8) 26 (29.6)  
Middle 133 (22.4) 107 (21.4) 26 (29.6)  
Low 265 (44.6) 229 (45.8) 36 (40.9)  
Quantity per week 
(*50g) (N=594)  
  
 
≤2500g per week 314 (52.9) 239 (47.2) 75 (85.2) <.01 
>2500g per week 280 (47.1) 267 (52.8) 13 (14.8)  
Drink tea     
Drinking tea (%)    <.01 
Yes 139 (7.5) 126 (12.0) 13 (1.6)  
No 1724 (92.5) 925 (88.0) 799 (98.4)  
Age start drinking 
tea (N=139) 29.9±23.9 
 
29.6±12.2 
 
32.5±12.6 .31 
Cups of tea per 
week 11.1±20.6 
 
11.5±10.9 
 
7.1±2.5  
    .15 
Types of tea    .30 
Green 108 (77.7) 71.9 (79.4) 8 (61.5)  
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Categorical variables were presented as number of subjects (row percentage) and tested by Fisher’s exact test. For numeric variables, the variables with 
normal distribution were expressed as mean ± SD and tested by independent samples Wilcoxon-Mann-Whitney test.  
 
 
 
 
 
 
 
 
 
 
 
Black 24 (17.3) 20 (15.9) 4 (30.8)  
Jasmine 5 (3.6) 4 (3.2) 1 (7.7)  
Drinking water      
Current drinking 
water (%)  
  
 .06 
tap 1844 (99.0) 1036 (98.6) 808 (99.5)   
well 19 (1.0) 15 (1.4) 4 (.5)   
Drank well water 
before (%)  
  
<.01 
Yes 1445 (77.6) 786 (74.8) 659 (81.2)  
No 418 (22.4) 265 (25.2) 153 (18.8)  
Years drank well 
water (N=1445) 10.2±14.9 
 
10.5±8.7 
 
9.8±6.1 .83 
Drank rive/ditch 
water before (%)  
  
.15 
Yes 1826 (98.0) 1025 (97.5) 801 (98.7)  
No 36 (1.9) 25 (2.4) 11 (1.4)  
Years drank 
rive/ditch water 
before (N=1826) 31.8±21.8 
 
 
32.4±11.3 
 
 
31.0±10.9 <.01 
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CHAPTER III. MENOPAUSAL STATUS MODIFIES THE EFFECT OF HEPATITIS B 
VIRUS ON LIVER DISEASE SEVERITY IN WOMEN: OBSERVATIONS FROM THE 
HAIMEN CITY COHORT 
 
3. 1. Abstract 
Background: Previous studies suggested that estrogen exposure in females might prevent females 
from having severe liver damage and developing liver cancer. This paper aims to determine 
whether reproductive factors may account for some of the differences in liver disease severity 
seen in women with chronic hepatitis B. 
Methods: We retrieved a sample of 791 female participants from a prospective cohort in Haimen 
City, China in 2003. Liver disease severity was categorized as “normal” and “abnormal” based 
on clinical diagnosis. Lifestyle and environmental exposures were measured by questionnaires. 
Reproductive history was used as a proxy measurement for estrogen exposure. We applied 
logistic regression models to estimate the association between female reproductive history and 
liver disease severity.  
Results: Compared to those who had HBeAg negative, females with HBeAg positive were more 
likely to have abnormal liver condition (OR: 12.4, 95% CI: 4.2-36.9). Postmenopausal women 
were more likely to develop abnormal liver condition (OR: 1.9, 95% CI: 1.2-3.1). Among those 
who are premenopausal, HBeAg positive does not significantly increase the odds of abnormal 
liver condition (OR: 1.5, 95% CI: 0.63-3.3). Among those who are postmenopausal, HBeAg 
positive associated with about a 35 times increased odds of abnormal liver condition (OR: 36.3, 
95% CI: 4.4-298.0). 
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Discussion: Postmenopausal women compared to premenopausal women had an increased risk 
for liver damage independent from age in the hepatitis B infected population. The combined 
effect of postmenopausal status and HBeAg seropositive is synergistic. This study provided 
evidence that estrogen exposure reduces the effect of hepatitis B viral replication on liver disease 
in chronic hepatitis B women.  
 
3.2. Background 
      Hepatitis B viral infection is associated with liver inflammation, cirrhosis, and hepatocellular 
carcinoma (HCC) [1, 2]. Most HCC patients with hepatitis B infection develop in the presence of 
liver fibrosis or cirrhosis [2, 3]. Despite the viral activity, there are a certain number of 
asymptomatic hepatitis B virus carriers that sustain little or no apparent liver damage during their 
life time [1, 2, 4]. Predicting those who will eventually develop liver damage provides important 
information for secondary prevention strategies [5, 6]. In the general population men are 2 to 4 
times more likely than women to develop liver cancer [7]. Among hepatitis B patients, males 
were more likely to develop more severe forms of chronic liver disease and have higher liver 
disease related mortality compared to women [8, 9]. Gender disparities in liver cancer have been 
consistently observed in animal studies as well [10, 11]. There are several hypotheses that could 
explain the gender disparity. One attributes this difference to the protective effect of estrogen in 
liver inflammation and the process of carcinogenesis [10]. However, in human population studies 
the results have been inconsistent [12-15]. This paper seeks to better understand the impact of 
estrogen exposure by examining the effect of reproductive history on the severity of liver disease 
in chronic hepatitis B (CHB) women. 
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3.3. Methods 
Study Population 
      The data in this study is derived from the Haimen City cohort, established in 1992-93 in 
Haimen City, China [8]. By the time of the 10 year follow-up, performed in 2003, there were 231 
participants who were hepatitis B carriers who had suffered chronic liver disease-related deaths. 
In 2003, the research team invited 2571 surviving HBsAg-positive cohort members to participate 
in an evaluation of their current liver disease status. There were 1863 (72.5%) participants that 
attended the evaluation. For the purposes of this analysis, we used information from 816 female 
participants. Because participants who were in the hepatitis B immune tolerant phase will only 
have minimum liver inflammation despite hepatitis B viral activity [4, 16], we excluded 21 
participants who were in the immune tolerant phase. The definition of immune tolerant status 
was based on McMahon’s summary of phases of CHB patients [4]: HBeAg seropositive, normal 
alanine aminotransferase (ALT≤35 units per liter), high viral load (≥105 copies/mL), and no 
indication of liver disease except liver cancer. The initial cohort study was reviewed and 
approved by the Institutional Review Board of the Fox Chase Cancer Center, Philadelphia, PA, 
USA, the Medical Ethics Review Group of Haimen City, China, and the Ethics Review 
Committee of the School of Public Health of Fudan University, Shanghai, China. 
Measurements 
      The details of data collection, laboratory methods, and diagnosis criteria were reported in 
previously published papers based on the same cohort [8, 9]. In short, subjects completed a brief 
questionnaire, received a physical and ultrasound exam of the liver, and had blood drawn to be 
tested for HBV markers and viral load, liver function tests, platelets, and prothrombin time. Liver 
disease severity was classified into five categories (normal, mild, moderate, severe, and liver 
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cancer). For the purpose of this analysis, we combined the five categories into normal liver 
condition and abnormal liver condition (referred to hereafter as “liver disease”). The liver disease 
category included all those with abnormal ALT or AFP, abnormal physical examination findings 
or laboratory test results indicative of liver disease, abnormal ultrasound findings indicative of 
active liver disease. The detailed definition can be also found in previously published papers 
done in the same cohort [8, 9].  
      Female reproductive history and exogenous estrogen exposures were ascertained on the 
questionnaire as number of pregnancies, live births, stillbirths, miscarriages, and abortions, time 
since last pregnancy, outcome of last pregnancy, menopausal status, age at menopause, age at 
menarche, ever took oral contraceptive (OC), currently take oral contraceptive (OC), ever took 
hormonal drug for post menopause, and ever took herbal medicine for post menopause.  
Statistical Methods 
      We used SAS 9.3 for all statistical analyses. All statistical tests were two-sided. We applied 
logistic regression models in the overall analysis. We first examined the crude bivariate 
association between each female reproductive history related variable and liver disease severity. 
For the purpose of analysis, we reclassified some of the continuous variables of reproductive 
information (such as number of pregnancies, live births, miscarriages, and abortions) into 
categorical variables in the bivariate analysis.  In order to understand the relation between 
reproductive history, hepatitis B viral activity, and liver disease, we constructed six models to 
predict the liver disease outcome in the multivariate analysis. Model 1 included HBeAg status, 
viral load, age, and menopausal status. Model 2 included all variables in model 1 and adjusted 
for other reproductive history and OC use. In order to evaluate a possible aggregate effect of a 
large number of reproductive variables on liver disease, we constructed a factor analysis based 
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on reproductive information and OC use. Five factors were extracted and incorporated into the 
model (shown in Appendices 3-1 to 3-3). To understand the hepatitis B viral activity and its 
impact on liver disease in pre- and postmenopausal women, we then constructed a stratified 
analysis by menopausal status. Since we detected heterogeneous effect of HBeAg status on liver 
disease in the stratified analysis, we then constructed the final model that included all variables 
in model 2 and the interaction term between HBeAg status and menopausal status.   
3.4. Results 
Basic characteristics 
      We included 791 female participants in this analysis. Table 3-1 shows the demographic and 
reproductive characteristics for all participants. The average age is 51.3±8.3 years old, and 
ranged from 34 to 75. Those who had indications of liver disease were slightly younger than 
those who did not (P<0.01). The time since last pregnancy was also slightly longer in those who 
did not have liver disease (P<0.01). In the liver disease group, there were more participants who 
had menopause due to surgery (P<0.01). There were more participants in the liver disease group 
than in the normal group who reported that they had taken oral contraceptives or were currently 
taking oral contraceptives (p=0.04 and 0.03, respectively).  
      Table 3-2 presents the hepatitis B viral serum markers of the participants. There are 4.6% of 
participants who were HBeAg seropositive, and most of them were in the liver disease group 
(P<0.01). A higher percentage of those who had high viral loads also had liver disease, while 
there were small differences among those who had viral loads in undetectable group or low viral 
load group (Ptrend<0.01). 
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Reproductive history and the odds of liver disease  
      Table 3-3 presents the crude bivariate association between reproductive related variables and 
OC use on liver disease. Although we did not observe a crude association between 
postmenopausal status and liver disease, postmenopausal status was associated with about a 2-
fold increase of likelihood of liver disease after adjusting for age and other covariates (Table 3-
4). Menopause due to surgery was a risk factor for liver disease (crude OR: 3.2 95% CI: 1.5-6.9) 
among postmenopausal women. Based on the crude analysis, the odds of liver disease increased 
by about 70% among those who had ever taken OC or were currently taking OC (OR: 1.7, 95% 
CI: 1.0-2.9, and OR: 1.7, 95% CI: 1.0-2.8, respectively).  This effect is consistent after adjusting 
for other covariates in model 2 (OR: 1.8, 95% CI: 1.0-3.1). However, OC use was not 
statistically significant in the stratification analysis based on menopausal status. Time since last 
pregnancy has a mild protective effect in the odds of liver disease (crude OR: 0.96, 95% CI: 
0.95-0.98) in the bivariate analysis. However it is not statistically significant after adjusting for 
other covariates in the multivariate analysis. We were not able to detect other associations 
between reproductive history and the prevalence of liver disease.  
      We also constructed a multiple logistic regression model using variables derived a from 
factor analysis to represent all the reproductive history and exogenous hormone use (shown in 
Appendices 3-1 to 3-3). In a model that included five factors from the factor analysis, factor 2 
shows a borderline significant effect (OR: 1.2, 95% CI: 1.0-1.5) on the increased risk of liver 
disease, and factor 4 shows a mild protective effect (OR: 0.78, 95% CI: 0.65-0.97) for liver 
disease (Appendix 3-3). Factor 2 indicated those who had more pregnancies, had more abortion 
experience, and currently or ever took OC associated with increased odds of liver disease. Factor 
4, which only explains about 10% of the variability of all reproductive history and exogenous 
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hormone use variables, suggested that those who had stillbirths and miscarriages had decreased 
odds of liver disease (Appendices 3-2 to 3-3).  
Hepatitis B viral activity and liver disease in premenopausal and postmenopausal women 
      HBeAg seropositive is an independent risk factor for liver disease, especially in 
postmenopausal women. Among all women, HBeAg seropositive associated with a 13 fold 
increased risk in liver disease (OR: 13.1, 95%CI: 4.4-39.1). We observed HBeAg seropositive 
had a heterogeneous effect on liver disease severity based upon women’s menopausal status. 
Among premenopausal women, we did not detect a significant association between HBeAg 
seropositivity and liver disease (stratum specific OR: 1.5, 95%CI: 0.6-3.3). However, we 
detected an HBeAg seropositive association with about a 36-fold increase in the odds of liver 
disease in post-menopausal women (stratum specific OR: 36.3, 95%CI: 4.4-298.0). In the 
analysis with the full dataset (Table 3-5), we used premenopausal women with HBeAg negative 
as a reference group for all other groups. The combined effect of postmenopausal status and 
HBeAg seropositive is an increase in the odds of liver disease by a factor of 60.6 compared to 
women who were premenopausal and HBeAg negative (OR: 60.6, 95% CI: 7.1-518.2). However, 
in the full dataset analysis the effect of HBeAg seropositive only associated with about a 7.5 fold 
increase of odds of liver disease in premenopausal women (OR: 7.5, 95% CI: 2.1-27.0). Figure 1 
demonstrates the log odds ratios of liver disease in different combinations of menopausal status 
and HBeAg seropositive. The results from the sensitivity analysis, which excluded those who 
have ever taken oral contraceptives, agree with the main analysis (Appendix 3-4). 
      High hepatitis B viral load (≥105 copies/mL) associated with a 2 fold increase in the odds of 
liver disease in the full dataset analysis (OR: 2.5, 95%CI: 1.5-4.2 in model 1, and OR: 2.3, 95% 
CI: 1.4-3.9 after adjusting for reproductive history). This effect remained significant in the 
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stratified analysis in premenopausal women (stratum specific OR: 3.1, 95% CI: 1.3-6.9). 
However, it is not significant in postmenopausal women (stratum specific OR: 1.7, 95% CI: 
0.86-3.5).  
3.5. Discussion 
      We observed that menopausal status modified the association between HBeAg and liver 
disease in the hepatitis B infected population. The combined effect of post-menopausal and 
HBeAg seropositive in liver disease is synergistic. HBeAg positive strongly associated with liver 
disease in postmenopausal women. Premenopausal women with HBeAg seropositive were 
associated with an approximately 7-fold increase in the likelihood of liver disease compared to 
premenopausal women with HBeAg seronegative, while postmenopausal women with HBeAg 
seropositive were associated with an approximately 60-fold increase in the likelihood of liver 
disease compared to those premenopausal women with HBeAg seronegative. Menopausal status 
is also an independent risk factor for liver disease. Post-menopausal women associated with an 
approximately 2 fold increased odds of having liver disease.  
       Our findings are consistent with the hypothesis that estrogen exposure reduced the effect of 
hepatitis B viral replication on liver disease in CHB women. HBeAg seropositive is an important 
indication for HBV viral replication [17], and it has been associated with liver disease severity 
and prognosis for the CHB population in previous studies [9, 18, 19]. There are two potential 
mechanisms that could explain the estrogen protective effect on liver disease in the CHB 
population [20]. In the first pathway, estrogen has a down regulation effect on HBV mRNA 
transcription [20, 21]. In the second pathway, estrogen suppresses the liver’s innate immune 
response and has a protective effect on liver disease progression in CHB patients [20].  Liu, et 
al’s study provided evidence that estrogen receptor ERα expression was decreased among most 
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female hepatocellular carcinoma patients [22]. Based on animal experiments, Naugler, et al 
proved that ERα plays a role in inhibiting Kuffer cell’s interleukin 6 (IL-6) production in the 
liver and protects female mice against liver damage [10]. Since IL-6 significantly increases when 
liver disease is exacerbated and during clearance of HBeAg [23], the evidence suggests that 
estrogen could play an important role in protecting females against inflammation induced liver 
damage during the virus clearance process. Our observations provide evidence to support the 
second pathway. Women after menopause experience a substantial decrease in endogenous 
estrogen exposure [24]. If HBV viral replication occurs during this period, postmenopausal 
women are likely to lose the estrogen protective affect against liver inflammation. This can 
explain why in our study, HBeAg only associated with about 7.5-fold increase in odds of liver 
disease in premenopausal women, while it associated with about 32-fold increase in odds of liver 
disease in postmenopausal women (Table 3-5).  
      We found high HBV viral loads (≥105 copies/mL) associated with about a 2 -fold increased 
odds of liver disease in model 2. We also detected high viral loads had a heterogeneous effect in 
odds of liver disease pre- versus postmenopausal women (OR: 3.1, 95% CI 1.4-6.9 in 
premenopausal women, and OR: 1.7, 95% CI: 0.86-3.5 in postmenopausal women). Although 
previous studies have suggested HBV viral load could predict long-term mortality from liver 
disease progression in the hepatitis B infected population [9], it is difficult to clearly identify its 
impact on current liver disease condition in cross-sectional observation. Depending on the 
immune phase, hepatitis B viral loads often change when patients move between immune active 
and inactive phases [4].  
      We have excluded 21 participants who were identified as likely to be immune tolerant by our 
criteria. Hepatitis B carriers who are in the immune tolerant phase often maintain no liver 
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inflammation for decades despite viral activity [4]. There is minimal liver damage and innate 
immune response to HBV among immune tolerant patients [4]. Thus, we believe our findings in 
the association between HBV viral activity on current liver disease is inapplicable to the HBV 
immune tolerant patients.  
      We observed that exogenous hormone use associated with increased risk of liver disease 
development in the hepatitis B infected population in the full dataset analysis, although the 95% 
confidence interval is borderline significant. Those who had ever or were currently taking oral 
contraceptive had about a 70% increased likelihood of liver disease based on our observations. 
However, this effect is not consistent in the stratified analysis in pre- and postmenopausal 
women. Although no previous studies present the association of the use of oral contraceptives 
and liver damage in chronic hepatitis B patients, animal studies provided some evidences that 
oral contraceptive steroids increase the likelihood of hepatocarcinogenesis in female mice [25, 
26]. Though some previous epidemiological studies failed to detect the increased risk of liver 
cancer due to oral contraceptive use [12, 15], it may be that the dose of oral contraceptive given 
to human beings did not reach the threshold of carcinogenesis. However, since oral contraceptive 
interferes with the ovarian cycle by suppressing natural estrogen production [27], it may reduce 
the estrogen protective effect against liver damage in hepatitis B patients.  
      In this study, we did not observe a significant association between women’s parity status and 
liver disease. To the best of our knowledge, there is no previous study that addressed the 
association between parity status and liver disease development among CHB patients. We also 
attempted to consider reproductive history and exogenous estrogen consumption as a combined 
effect using factor analysis. One of the factors suggested that those with more pregnancies, those 
with more abortion experience, and those who currently or ever took oral contraceptives 
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increased the odds of liver disease. However, we were not able to quantify these individual 
affects in the model. Previous studies have provided controversial evidence regarding female 
reproductive history and liver cancer [13, 15, 28]. In Yu, et al’s [15] study, the number of full 
term pregnancies did not show a statistically significant protective effect on liver cancer among 
the hepatitis B infected population, however it is a protective effect to liver cancer in the overall 
population. Tzonou’s study [28] suggested that parity status has a dose-response increases risk 
associated with the development of liver cancer. Compared to those who had one or two 
children, nulliparous women were 0.6 times as likely to develop liver cancer, women with three 
and four children were 1.3 times as likely to develop liver cancer, and women with five and more 
children were 1.7 times as likely to develop liver cancer. However, their study was a relatively 
small sample size case-control study. In La Vecchia’s study, the relative risk of HCC for parous 
vs. nulliparous women was 2.6 (95% CI: 1.2-5.8). This risk presents a dose response effect: the 
relative risk of HCC for one child was 2.1, for 2 children was 2.6, for 3 children was 3.2, and for 
4 or more births was 3.5 (chi square trend = 6.49, p = 0.01) [13]. During the later stage of 
pregnancy, especially the third trimester, females will experience about 100 times the regular 
exposure of estrogen [29]. However, there is no substantial estrogen increase during the early 
stage of pregnancy [30]. Based on our observation and the controversial results from previous 
studies done in liver cancer [13, 15, 28], it might suggest that reproductive history as a proxy 
measurement for lifetime estrogen exposure only suggesting a high dose exposure of estrogen for 
a short amount of time, but it might not be able to predict liver disease progression. The direct 
measurement of estrogen level during different periods in female lifetimes might be helpful to 
clarify this association. 
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      In this population, time since last pregnancy shows a mild protective effect in liver disease. 
However, it is not statistically significant after adjusting for other variables in the multivariate 
analysis. We also found those who have liver disease were slightly older than those who without 
liver disease. We have concluded this mild protective effect from time since last pregnancy and 
age are due to the fact that the older age survivors from this cohort might have better overall 
health. Age does not have a linear association with liver disease in this study. Although there 
might be survivorship bias in the older age participants, we do not believe it will change the 
association between the combined effect of HBeAg positive and menopausal status on liver 
disease. 
      Our study is limited by the cross-sectional study design, which restricts our ability to 
determine causality. The HBV viral load were measured only one time in 2003, thus we were not 
able to monitor the change of viral load through different time points in this study. This limits 
our ability to further study the association between viral activity on liver disease. Although we 
observed that the association between menopausal status modified the association between 
HBeAg positive and liver disease, our finding needs to be validated in a long-term prospective 
cohort study. In addition, due to the nature of cross-sectional study design, we were only able to 
identify participant’s immune phase (immune tolerant or not) based on the cross-sectional 
information. As the clinical diagnosis of the hepatitis B immune tolerant phase often relies on 
patient’s previous history of liver condition, we might have misclassified some participants who 
previously had liver inflammation but recovered at the point of data collection as immune 
tolerant. Third, we had a limited number of participants who had ever used hormonal 
replacement therapy after menopause in this Chinese group. Thus, we do not have enough power 
to detect the effect of hormonal replacement therapy on liver disease. Further studies of 
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populations in which hormonal replacement therapy is more commonly used should be 
considered. 
      Our study has certain strengths. To the best of our knowledge, we are the first study to 
investigate the relationship between female reproductive factors and liver inflammation-related 
damage in hepatitis B infected patients. We are also the first group to report that female 
menopausal status modified the effect of HBeAg positive in liver disease in a study with a large 
sample size. Our results enrich the evidence to support the theory that estrogen protects females 
against inflammation induced liver damage in the human population. This paper also provides a 
potential pathway to explain the gender disparity in liver cancer development.  
3.6. Conclusions 
      Female postmenopausal status is an independent risk factor for liver disease in the hepatitis B 
infected population. HBeAg positivity had a stronger association with presence of clinical liver 
disease among post-menopausal versus pre-menopausal women. Oral contraceptive use is 
borderline significant associated with liver disease in our observation. We were not able to 
quantify the association between other reproductive history variables (number of pregnancies, 
number of live births, number of stillbirths, number of miscarriage, and number of abortions) and 
liver disease. However, our results from factor analysis suggest the aggregate effect of 
reproductive history associated with the odds of liver disease. Further evaluation of the causal 
relation through a long-term prospective cohort study in a hepatitis B infected population is 
recommended.  
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Tables and figures 
Table 3-1. Basic characteristics and liver disease status among female participants in Haimen 
City cohort in 2003  
Variable  Total  Liver disease status 
 (n = 791) No 
indication of 
liver disease 
(N=526) 
Indication of 
liver disease 
(N=265) 
P-value 
Age 51.3±8.3 52.0±8.7 49.9±7.4 <0.01** 
30-40 years old 36 (4.6) 22 (4.2) 14 (5.3) 0.046▲ 
41-50 years old 328 (41.5) 205 (39.0) 123 (46.4)  
51-60 years old 298 (37.7) 201 (38.2) 97 (36.6)  
>60 years old 129 (16.3) 98 (18.6) 31 (11.7)  
Numbers of 
pregnancies 
2.5±1.4 2.5±1.4 2.5±1.4 0.80* 
0 8 (1.0) 6 (1.1) 2 (0.8) 0.82§ 
1-2 459 (58.0) 302 (57.4) 157 (59.3)  
≥3 324 (41.0) 218 (41.4) 106 (40.0)  
Number of live 
births 
1.7±1.2 1.8±1.2 1.6±1.0 0.30* 
0 22 (2.8) 16 (3.0) 6 (2.3) 0.49§ 
1 425 (53.7) 275 (52.3) 150 (56.6)  
≥2 344 (43.5) 235 (44.7) 109 (41.1)  
Ever had 
stillbirths 
 
No 
 
 
779 (98.5) 
 
 
514 (97.7) 
 
 
265 (100.0) 
0.03§ 
Yes 12 (1.5) 12 (2.3) 0  
Number of 
miscarriages 
0 
 
 
753 (95.2) 
 
 
497 (94.5) 
 
 
256 (96.6) 
0.25§ 
1 30 (3.8) 24 (4.6) 6 (2.3)  
≥2 8 (1.0) 5 (1.0) 3 (1.1)  
Number of 
abortions 
 
 
0.7±0.9 
 
 
0.6±0.9 
 
 
0.8±1.0 
0.02* 
0 440 (55.6) 307 (58.4) 133 (50.2) 0.09▲ 
1 209 (26.4) 132 (25.1) 77 (29.1)  
≥2 142 (18.0) 87 (16.5) 55 (20.8)  
Time since last 
pregnancy 
22.4±8.9 23.2±9.1 20.8±8.4 <0.01* 
Outcome of last 
pregnancy 
   0.62§ 
Live birth 497 (63.6) 335 (64.6) 162 (61.6)  
Miscarriage 284 (36.3) 183 (35.3) 101 (38.4)  
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Stillbirth 1 (0.1) 1 (0.2) 0  
Menopausal status 
Postmenopausal 
 
420 (53.1) 
 
285 (54.2) 
 
135 (50.9) 
0.39▲ 
Premenopausal 371 (46.9) 241 (45.8) 130 (49.1)  
Age at menopause 
(N=420) 
48.8±4.3 49.0±4.2 48.4±4.7 0.34* 
Reason of 
menopause 
(N=420) 
    
 
<0.01§ 
Surgery 18 (4.3) 7 (2.5) 11 (8.2)   
Natural 398 (94.8) 277 (97.2) 121 (89.6)   
Age at start of 
menstruation 
16.4±1.8 16.4±1.8 16.3±1.7 0.67* 
Years of having 
menstruation 
30.5±5.0 30.7±4.9 30.2±5.0 0.16* 
Ever took oral 
contraceptive 
   0.04▲ 
No 724 (91.9) 488 (93.3) 236 (89.1)  
Yes 64 (8.1) 35 (6.7) 29 (10.9)  
Current take oral 
contraceptive 
   0.03▲ 
No 728 (92.0) 492 (93.5) 236 (89.1)  
Yes 62 (7.8) 33 (6.3) 29 (10.9)  
Ever took 
hormonal drug 
for menopause 
(N=420) 
   0.10 § 
No 418 (99.5) 285 (100.0) 133 (98.5)  
Yes 2 (0.5)  0 2 (1.5)  
Took herbal 
medicine for post 
menopause 
(N=420) 
   0.54 § 
No 418 (99.5) 284 (99.7) 134 (99.3)  
Yes 2 (0.5) 1 (0.4) 1 (0.7)  
** T test  
* Wilcoxon rank test 
§ Fisher’s exact test 
▲ Chi-square test 
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Table 3-2. Hepatitis B viral activity and liver condition characteristics in Haimen city cohort in 
2003 
Variable  Total  Liver disease status 
 (n = 791) No 
indication of 
liver disease 
(N=526) 
Indication of 
liver disease 
(N=265) 
P-value 
HBeAg Status (%) 
Negative 
 
755 (95.5) 
 
521 (99.1) 
 
234 (88.3) 
<0.01§ 
Positive 36 (4.6) 5 (1.0) 31 (11.7)  
HBV viral load 
Undetectable 
(<1.6×103 
copies/mL) 
 
 
 
122 (15.4) 
 
 
 
92 (17.5) 
 
 
 
30 (11.3) 
<0.01^ 
Low viral load 
(<105 copies/mL) 
 
423 (53.5) 
 
305 (58.0) 
 
118 (44.5) 
 
High viral load 
(≥105 copies/mL) 
 
246 (31.1) 
 
129 (24.5) 
 
117 (44.2) 
 
§ Fisher’s exact test 
^ Cochran-Armitage Trend test 
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Table 3-3. The crude association between women reproductive information and 
indication of liver disease 
Variable  OR for liver disease 95% CI 
 (n = 791)  
Number of pregnancies   
0 (N=8) 1 reference 
1-2 (N=459) 1.6  0.3-7.8 
≥3 (N=324) 1.5 0.3-7.34 
Number of live births   
0 (N=22) 1 Reference 
1 (N=425) 1.5 0.6-3.8 
≥2 (N=344) 1.2 0.5-3.3 
Number of miscarriages 
0 (N=753) 
 
1 
 
Reference 
1 (N=30) 0.49 0.20-1.2 
≥2 (N=8) 1.2 0.3-4.9 
Number of abortions   
0 (N=440) 1 reference 
1 (N=209) 1.4 0.95-1.9 
≥2 (N=142) 1.5 0.98-2.2 
Time since last pregnancy 0.97 0.95-0.98 
Outcome of last pregnancy   
Live birth (N=497) 1 reference 
Miscarriage (N=285) 1.1 0.84-1.6 
Menopausal status  
Premenopausal (N=371) 
 
1 
 
reference 
Postmenopausal (N=420) 0.88 0.65-1.2 
Age at menopause 
(N=420) 
 
0.97 
 
0.93-1.0 
Reason of menopause 
(N=420) 
  
Natural (N=18) 1 reference 
Surgery (N=398) 3.2 1.5-6.9 
Age at start of menstruation 0.97 0.89-1.1 
Years of having 
menstruation 
0.98 0.95-1.0 
Ever took oral 
contraceptive 
  
No (N=724) 1 reference 
Yes (N=64) 1.7 1.0-2.9 
Current take oral 
contraceptive 
  
No (N=728) 1 reference 
Yes (N=62) 1.7 1.0-2.8 
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Table 3-4. The association between reproductive history, oral contraceptive use, and present of liver disease 
 Model 1 
AIC: 925.22 
-2log L 913.22 
Model 2 
AIC: 930.36 
-2log L: 904.36  
premenopausal 
women only 
N=364 
postmenopausal 
women only 
N=415 
age 0.94 (0.91-0.97) 0.95 (0.91-0.99) 0.99 (0.92-1.1) 0.91 (0.86-0.97) 
HBeAg positive 12.4 (4.2-36.9) 13.1 (4.4-39.1) 1.5 (0.63-3.3) 36.3 (4.4-298.0) 
Viral load low vs. 
undetectable 
1.3 (0.83-2.2) 1.2 (0.76-2.0) 1.6 (0.77-3.4) 0.96 (0.49-1.9) 
Viral load high vs. 
undetectable 
2.5 (1.5-4.2) 2.3 (1.4-3.9) 3.1 (1.4-6.9) 1.7 (0.86-3.5) 
Postmenopause vs. 
premenopause 
1.9 (1.2-3.0) 1.9 (1.2-3.1)   
Time been 
pregnant 
 0.6 (0.3-1.3) 0.39 (0.10-1.5) 0.88 (0.34-2.3) 
Number of live 
birth 
 1.7 (0.8-3.5) 3.7 (0.98-14.3) 1.3 (0.51-3.4) 
Number of 
miscarriage 
 1.1 (0.45-2.9) 2.1 (0.38-11.7) 0.86 (0.27-2.7) 
Number of 
abortion 
 1.8 (0.83-3.8) 3.1 (0.80-12.0) 1.1 (0.42-3.0) 
Time to last 
pregnancy 
 0.98 (0.95-1.0) 0.97 (0.92-1.0) 0.98 (0.94-1.0) 
Outcome of last 
pregnancy 
    
Live birth   1 1 1 
Miscarriage  0.85 (0.56-1.3) 0.77 (0.42-1.4) 1.0 (0.56-1.9) 
Age at start of 
menstration 
 1.0 (0.96-1.1) 1.1 (0.96-1.2) 0.99 (0.89-1.1) 
Ever took oral 
contraceptive 
 1.8 (1.0-3.1) 1.3 (0.65-2.7) 2.0 (0.88-5.0) 
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Table 3-5. The association between the combined effect of menopausal status and 
HBeAg serostatus on liver disease in Haimen city cohort in 2003 
 OR for having liver 
disease 
OR for having liver 
disease 
Premenopausal HBeAg03- 1 (reference) 1 (reference) 
HBeAg03+ 7.5 (2.1-27.0) 7.5 (2.1-27.0) 
Postmenopausal HBeAg03- 1.9 (1.2-3.1) 1 (reference) 
HBeAg03+ 60.6 (7.1-518.2) 31.9 (4.0-257.7) 
 
 
 
 
 
Figure 3-1. Log odds ratios and standard errors of liver disease in different combination 
of HBeAg status and menopausal status.   
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Appendices 
Appendix 3-1. Plots for cumulative and individual proportion of variance explained by 
each factor in factor analysis. Statistics are shown in Appendix 3-2. 
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Appendix 3-2. Standardized scoring coefficients in five reproductive related factors 
derived from factor analysis  
  Factor1 Factor2 Factor3 Factor4 Factor5 
Number of pregnancies  0.13806227 0.33457231 -0.2090011 -0.0359571 -0.1633756 
Number of live births 0.26204205 0.15109603 0.00093607 -0.1423346 -0.2294208 
Number of stillbirths  0.0190943 0.00576654 -0.0378467 0.63966958 -0.0496246 
Number of miscarriages -0.0200044 0.08534772 0.0592283 0.5838692 -0.3644865 
Number of abortions -0.099398 0.28681986 -0.3281197 -0.1538421 0.15325616 
Time since last 
pregnancy 
0.2823243 0.0011897 0.16357566 -0.0118745 0.01624974 
Outcome of last 
pregnancy  
-0.129038 0.22455575 -0.2937024 0.14834443 0.12753849 
Age at menarche 0.05163531 0.01551584 0.06204359 0.21310052 0.79251073 
Age at menopause 0.19926559 0.10337679 0.04671855 0.16879774 0.26423859 
Reason of menopause 0.2591576 0.09239272 0.059331 -0.0378398 0.04664966 
Took oral contraceptive 
before 
-0.1394683 0.25997431 0.41186946 -0.0404742 0.00656268 
Current take oral 
contraceptive  
-0.1386102 0.26062394 0.40851005 -0.0609862 0.00949727 
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Appendix 3-3. Association between HBeAg serostatus, viral load, reproductive history and abnormal liver condition in chronic 
hepatitis B female 
 ORs and 95% CIs in m with factors from 
factor analysis 
age 0.95 (0.91-0.99) 
HBeAg positive 12.1 (4.1-36.0) 
Viral load low vs. undetectable 1.2 (0.76-2.0) 
Viral load high vs. undetectable 2.4 (1.4-3.9) 
Factor 1 1.1 (0.77-1.6) 
Factor 2 1.2 (1.0-1.5) 
Factor 3 1.1 (0.91-1.2) 
Factor 4 0.78 (0.63-0.97) 
Factor 5 1.1 (0.91-1.3) 
 
 
 
Appendix 3-4. Sensitivity analysis for the association between the combined effect of menopausal status and HBeAg on liver disease 
in full dataset analysis exclude those who ever took oral contraceptive participants (N=716) 
 ORs for having liver 
disease 
ORs for having liver 
disease 
Premenopausal HBeAg03- 1 (reference) 1 (reference) 
HBeAg03+ 7.8 (2.2-28.4) 7.8 (2.2-28.4) 
Postmenopausal HBeAg03- 1.9 (1.1-3.1) 1 (reference) 
HBeAg03+ 63.9 (7.4-554.0) 34.2 (4.2-278.2) 
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CHAPTER IV. GENDER DIFFERENCE IN HEPATITIS B VIRAL LOAD IN 
HEPATITIS B VIRAL LOAD CHANGE OVER TIME AND ITS ASSOCIATION WITH 
LIVER DISEASE IN CHRONIC HEPATITIS B PATIENTS 
4.1. Abstract 
Background: Previous studies have noted a significant gender difference in the risk of liver 
cancer among hepatitis B chronic infection patients. Some indicated sex hormone might play a 
part in the regulation of hepatitis B viral replication. This paper aims to examine hepatitis B viral 
load change over time among men and women and determine how this change may predict liver 
disease. 
Methods: We retrieved a sample of 1863 participants from a prospective cohort in Haimen City, 
China in 2003. Liver disease severity was categorized as “normal” and “abnormal” based on 
clinical diagnosis. We applied the mixed model with random intercepts and random slopes to 
predict the change of viral load in 10 years. We applied the logistic regression model to estimate 
the association between viral load change and liver disease condition in 2003.  
Results: Hepatitis B viral load decreased over time in both males and females (p-value<0.01). 
Viral load among males decreased more dramatically than for females over the 10 year period 
(p-value<0.01). Viral load over 10^(5) copies/ml is an independent risk factor for liver disease in 
the chronic hepatitis B population (OR: 4.8, 95% CI: 2.6-8.8).  
Conclusions: Androgen might serve as an up-regulate hepatitis B viral replication. HBV viral 
replication among males might decrease dramatically due to the androgen exposure decrease 
over time. Antiviral therapy should be seriously considered when patients have a high viral load, 
especially in male chronic hepatitis B patients. 
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4.2. Background 
       Hepatitis B virus (HBV) infection is linked to a series of liver complications such as 
inflammation, fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related death [1-3]. Among 
the chronic hepatitis B (CHB) infected population, however, some sustain no or minimal liver 
damage through their life time [2-4]. Predicting who will develop liver damage or liver cancer is 
important for disease management among CHB patients [5, 6]. It is well-established that males 
are more likely to develop severe forms of liver disease compared to female CHB patients [7, 8]. 
The mechanism behind this has been explored in animal studies and some cohort studies [9]. 
Animal studies support the theory that hepatitis B viral load might be regulated by sex hormones 
[10-12]. Whether or not sex hormones influence HBV viral load in the human population 
remains understudied. Previous studies have observed that hepatitis B viral load is associated 
with an increased risk of severe liver disease and hepatocellular carcinoma (HCC) [8, 13]. In the 
Taiwan population, hepatitis B viral load over 10^(4) copies/mL at baseline associated with a 2-
fold increased risk of liver cancer [13]. In Chen, et al.’s study, viral load over 10^(5) copies/ml 
associated with 11.2 times in risk of HCC [8]. It is a challenge to measure HBV viral load 
change over time and use it as a disease biomarker because hepatitis B viral load fluctuates over 
time [14]. Most CHB patients have higher viral loads earlier in their life due to their immune 
status [15]. The aim for this study is to examine HBV viral load change over time among men 
and women and determine how this change may predict later liver disease. 
4.3. Methods 
Study population 
      The data in this study is derived from the Haimen City cohort, established in 1992-93 in 
Haimen City, China [7]. In 2003, we invited 2571 confirmed HBsAg positive cohort members 
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from 9 townships to participate in an evaluation of their current abnormal liver status. There 
were 1863 (72.5%) participants that attended the evaluation. The study was reviewed and 
approved by the Institutional Review Board of the Fox Chase Cancer Center, Philadelphia, PA, 
USA, the Medical Ethics Review Group of Haimen City, China, and the Ethics Review 
Committee of the School of Public Health of Fudan University, Shanghai, China. The initial 
cohort included 90,836 adults from 35 towns in Haimen, China. 
Measurements 
      Liver disease severity in 2003 was broken down into five categories (normal, mild, moderate, 
severe, and liver cancer) based on the patients’ physical and ultrasound exam and serum tests 
performed in 2003. For the purpose of the current project, we have collapsed the five level liver 
disease severity scale into two categories (normal liver status, and abnormal liver status), and 
four categories (normal, mild, moderate, and severe/liver cancer). The serum samples were 
stored in a temperature of -20°C environment in Philadelphia and retrieved in 2003 for viral load 
testing using real time PCR. We used the TaqMan PCR assay to detect viral nucleic acids in 
order to quantify the HBV viral load [16]. The details of the method can be found in previous 
published papers based on our cohort [8, 17]. The limit of detection for viral load through this 
method is 1.6x10^(3) copies/ml. 
Statistical analysis 
           We used SAS 9.3 for all statistical analyses. All statistical tests were two-sided. 
Descriptive statistics for social and demographic factors and viral markers were tested through 
the appropriate statistical test (Table 4-1). The HBV log viral load change over time was tested 
through multivariate analysis of variance (MANOVA) using Wilk’s lambda statistic, and the 
random mixed model for the repeated measurement in two time points (1993 and 2003). Both 
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MANOVA and random mixed models were used to detect the gender difference in log viral load 
based on models that included age, HBeAg serum status, and log viral load in two time points as 
independent variables. The MANOVA test was mainly used to show the log viral load change in 
the population mean, and the random mixed model was used to show the within-subject log viral 
load change over time.  
      We modeled the association between log viral load change and liver disease severity in 
several different ways. We first categorized log viral load in 1993 and 2003 into 9 categories (3 
categories log viral load in 1993 by 3 categories log viral load in 2003), and then used the 9 
categories to predict the liver disease severity in a logistic regression model (in the 2 categories 
abnormal liver status outcome) and a multinomial regression model (in the 4 categories liver 
disease outcome). Since we are also interested in the difference of the log viral load between 
1993 and 2003, we calculated the difference of log viral load between the two time points and 
predicted the liver disease severity in 2 categories using a logistic regression model.  
4.4. Results 
Basic characteristics 
      Table 4-1 shows the basic characteristics of the participants and their viral markers. Among 
all participants, the abnormal liver status group is slightly younger than the normal liver group 
(Pt-test<0.01). About 56% of the participants are males. Males are more likely to have abnormal 
liver status compared to females (Pchi-square<0.01). There is no difference in occupation between 
normal and abnormal liver status (Pchi-square=0.36). Among the 1863 participants, 48 (4.5%) were 
identified as likely to be in the immune tolerant phase of CHB. The definition criteria were based 
on McMahon’s summary of phases of CHB patients [4], which denoted immune tolerance in 
CHB is characterized by  HBeAg seropositivity, normal alanine aminotransferase (ALT≤35 units 
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per liter), high viral load (≥10^(5) copies/mL), and no indication of abnormal liver function 
except liver cancer. Due to the definition, all immune tolerant participants had normal liver 
function and were HBeAg positive.  Despite this, those who were HBeAg seropositive in 2003 
were more likely to be in the abnormal group than in the normal liver group (Pchi-square<0.01). 
Those with high viral load (≥10^(5) copies/mL) in both 1993 and 2003 were more likely to be in 
the abnormal group than the normal liver group. The Cochran-Armitage test indicated there is a 
statistically significant trend in the prevalence of abnormal liver status by log viral load group 
(Ptrend<0.01 in both 1993 and 2003).  
Hepatitis B log viral load change over time  
      We observed an overall HBV log viral load decrease over the 10 year period. In 1993, the 
mean log viral load was 5.3±1.9, while the mean log viral load was 4.6±1.6 in 2003 (Pttest<0.01). 
Based on MANOVA, the least square mean log viral load for men in 1993 was 10^(5.6) and was 
10^(5.0) for women after adjustment of age and HBeAg status. There was a statistically 
significant difference of log viral load in 1993 by gender (PWilks’ Lambda<0.01). The least square 
mean log viral load, however, shows no difference by gender in 2003 (mean for males: 10^(4.6) 
and for females 10^(4.7), respectively). The MANOVA test also indicated that there is a 
statistically significant interaction between time and gender (PWilks’ Lambda<0.01). The slope 
indicated male log viral load is much steeper than that in women. Figure 1 displayed the mean 
least square log viral load change over time by gender.  
      The same pattern of log viral load change by gender also appeared in the random mixed 
model that was based on participants’ within-subject change. Table 4-2 presents the fixed effect 
solution from the random mixed model. It indicated that time, gender, age, HBeAg status, and 
the interaction between time and gender are all statistically significant predictors of log viral load 
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change. The estimate of log viral load for males is 1.1 higher than females at baseline (1993). 
The estimate of time effect is dependent on gender, which is -0.77 in males and -0.31 in females 
(P<0.01). This indicates that the decrease of log viral load in males is more dramatic than that in 
females. Additionally, those who were HBeAg seropositive in 2003 had a log viral load 3.4 
higher than those who were HBeAg seronegative (P<0.01).  
Log viral load change and liver disease severity 
      Table 4-3 presents the odds of abnormal liver status in 2003 by log viral load in 1993 and 
2003. We treated those with undetectable viral loads in both time points as the reference group. 
Those who had high viral loads (≥105 copies/mL) in 2003 consistently associated with increased 
odds of abnormal liver status regardless of the viral load at cohort entry in 1993. Among those 
who had high viral load in 2003, those who had undetectable viral load in 1993 were 2.3 times as 
likely to have abnormal liver status in 2003 (95% CI: 1.1-4.8); those who had low viral load in 
1993 were 2.0 times as likely to have abnormal liver status in 2003 (95% CI: 1.1-3.9); and those 
who had high viral load in 1993 were 4.8 times as likely to have abnormal liver status in 2003 
(95% CI: 2.6-8.8). These effects are consistent after we adjusted for age and HBeAg status. In a 
stratified analysis, we observed the same effect in the stratum specific odds ratio by male and 
female. We detected the effect of high viral load in 2003 is stronger in women than in men 
(Table 4-3).  
       In the sub-population that have HBeAg seronegative, we observed the same gender 
difference in the association between high viral load and abnormal liver status. Among female 
participants, high viral load in 2003 associated with 5.2 (95% CI: 1.0-26.7), 5.2 (95% CI: 1.1-
24.2), and 10.8 (95% CI: 2.3-50.1) times increased odds of abnormal liver status depending on 
their viral load in 1993. Among male participants, high viral load in 2003 associated with 2.5 
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(95% CI: 0.91-7.1), 2.4 (95% CI: 1.1-5.2), and 5.6 (95% CI: 2.5-12.2) times increased odds of 
abnormal liver status depending on their viral load in 1993. Sensitivity analysis that excluded 48 
participants who were considered in the immune tolerant phase also agrees with the above 
findings (Appendix 4-2). In the model that treated liver disease severity as 4 categories (shown 
in Appendix 4-1), those with high viral loads in 2003 were also more likely to have at least mild 
liver disease or severe liver disease in the population.  
      We found the difference of log viral load between 1993 and 2003, log viral load in 1993, and 
age are statistically significant (p=0.02, <0.01, and <0.01, respectively) in a logistic regression 
model that predict the probabilities of abnormal liver status in 2003. Figures 4-2 and 4-3 display 
the predicted probabilities for abnormal liver status and 95% confidence interval by the 
difference of log viral load between 1993 and 2003 in males and females. The probability for 
abnormal liver status for females gradually decreased, while the graph for males shows a deep 
convex.  Figure 4-3 shows that the greater difference between these two time points, the higher 
the probability of abnormal liver status in males. This is especially true for those who had viral 
loads higher in 2003 and lower in 1993 (showed as the negative value of log viral load 
difference).  
4.5. Discussion 
       We discovered that although mean HBV log viral load for males and females both decreased 
over time in this population, the slope of log viral load decrease differs by gender. Based on our 
observation, males often had higher log viral load at the beginning of the study compared to 
females, but then dropped faster than females at the end of the study. The predicted decrease of 
log viral load over time for males is 0.77 and for females is 0.33 in 10 years’ time. Based on our 
observation, high viral loads (≥105 copies/mL) in 2003 associated with increased odds of 
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abnormal liver status regardless of the past viral load. There is a gender difference in the effect of 
high viral load on abnormal liver status. We observed both males and females with high viral 
load always associated with increased odds of abnormal liver status despite the viral profile in 
1993.  
      Previous studies have also observed that older CHB patients have lower viral load compared 
to younger patients [18].  CHB patients, especially those who were infected through perinatal 
transmission, often experience several decades in the immune tolerant phase [4, 19]. During this 
phase, patients would have high viral load and be HBeAg seropositive but have minimum liver 
damage [4, 19]. Most patients at later points of their life enter the immune active phase and the 
immune inactive phase. During these phases, patients often develop anti-HBe through adaptive 
immunity and begin clearance of the HBV virus [4, 19]. This phenomenon could explain the 
HBV viral load decrease in the population.  
      To our knowledge, the gender difference on the decrease of viral load over time in the human 
population has not been reported in previous studies. Tian, et al. observed that androgen-
stimulated androgen receptor (AR) increased HBV transcription [12]. They also identified two 
androgen response elements (ARE) located in HBV nucleotide (913-927 and 949-963) enhancer 
I. These ARE were available for binding in various HBV genotypes [10-12]. Therefore, high 
serum androgen in males could up-regulate HBV gene transcription and encourage high viral 
load in males [10-12]. Based on previous studies, men have been shown to experience androgen 
decrease over time [20, 21]. Our findings suggest that the decrease of endogenous androgen in 
males might decrease HBV transcription and is associated with a decreased viral load in males.  
    Wang, et al. have shown that estrogen receptors (ERα) reduced the overall HBV mRNA 
transcription by modulating the activity of HBV enhancer I, which would down regulate HBV 
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transcription [22]. Because estrogen levels decrease over time in women[23], this might also 
explain the decrease of viral load among females. Our observation is consistent with the 
hypothesis that the androgen up regulation effect is stronger than the estrogen down regulation 
effect on HBV transcription in the human population. There is very little difference in viral load 
among men and women later in their life in this study population.  
      We observed that high viral load (≥10^(5) copies/mL) in 2003 predicted increased odds of 
abnormal liver status in this population. Previous published papers based on this population have 
disclosed that the past viral load predicted liver disease mortality and hepatocellular carcinoma 
(HCC) [8]. Also, previous studies done in other populations have also suggested that viral 
load≥10^(5) copies/mL is a predictor of high mortality from liver disease and HCC [8]. Both 
males and females with high viral load in 2003 have a consistent increase of odds of abnormal 
liver status regardless of their viral load in 1993. Women with high viral load in 2003 associated 
with higher odds of abnormal liver status compared to men, regardless the viral load in 1993.   
      Although we did not observe that HBeAg seropositive in 2003 increased the odds of 
abnormal liver status in the full population model, we observed it in the sensitivity analysis that 
excluded the putative immune tolerant participants. Males with HBeAg positive associated with 
a 14 fold (OR: 14.8, 95% CI: 3.5-63.2) increased odds of abnormal liver status, while females 
with HBeAg positive associated with a 7 fold (OR: 7.1, 95% CI: 2.6-19.8) increased odds of 
abnormal liver status. Previous studies have provided evidence that estrogen exposure in females 
could protect female CHB patients from liver cancer and liver damage [24, 25]. Animal studies 
also indicated that ERα inhibits Kupffer cell’s interleukin 6 (IL-6) production in the livers of 
mice’s and protects female mice against liver damage [26]. Since IL-6 significantly increases 
when liver disease is exacerbated and during clearance of HBeAg [27], the evidence suggests 
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that estrogen could play an important role in protecting females against inflammation induced 
liver damage during the virus clearance process.  
      We observed that those who had greater increases of viral load in the 10 year time associated 
with a higher probability of abnormal liver status in 2003, especially in men (Figures 4-2 to 4-3). 
We agree with McMahon’s study that the fluctuation of HBV viral load might indicate a higher 
risk of liver damage [28]. This effect is observed more clearly in males than in females. The left 
side of both curves (the negative value) shows the probability of abnormal liver status when 
higher viral loads appeared in 2003, and the right side (the positive value) shows the probability 
of abnormal liver status when higher viral loads appeared in 1993. It is again consistent with the 
earlier finding that viral load in 2003 suggests a high probability of abnormal liver status.  
      Our study is limited by several aspects. First, we have tested the HBV viral load from both 
time points in 2003. The transportation and long term storage of samples might influence the 
sensitivity and specificity of the viral load measurement for 1993 compared to 2003. There are 
potential measurement errors in this process. However, there is no evidence suggesting 
differential bias. Second, we were only able to observe viral load changes over a 10 year period 
through two repeated measurements. Since viral load fluctuates among CHB patients, additional 
time points for repeated measurement of viral load will be useful to identify the viral load change 
and the trend more precisely. Since HBV viral load is a predictor of liver damage and HCC, we 
encourage future prospective studies with repeated measurement of HBV viral load to validate 
our findings. Last but not least, the population used in this study are the survivors, ten years after 
cohort entry. During the 10 year follow-up, 231 participants who were hepatitis B carriers had 
suffered chronic liver disease-related deaths. We are unable to observe the viral load change 
among those who were lost-to-follow-up due to liver disease related death.  
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      Our study also has certain strengths. We are the first group to report the trend of HBV viral 
load change over time using longitudinal data that observed the within-subject change over time. 
Previous studies have provided findings only based on cross-sectional observation [14, 18]. In 
addition, we are the first group to report the gender difference on viral load change over time 
using longitudinal data. Our findings provided population-based evidence to support the 
hypothesis that androgen might play a role in up regulation of HBV mRNA transcription. Last 
but not least, we provided evidence that there is a gender difference in the effect of HBV viral 
load change on liver disease.  
4.5. Conclusion 
     Among subjects with CHB who survived over a ten year period, HBV viral load decreased 
more dramatically in males than in females. Viral load over 10^(5) is an independent risk factor 
for liver disease among CHB. There is a gender difference in the association between viral load 
and liver disease. Current high viral load is associated with increased odds of liver disease in 
males. This effect is independent from males’ past viral load exposure. It suggests that antiviral 
therapy should be highly considered when patients have viral load over 10^(5), especially in 
male CHB patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
References 
1. Dienstag, J.L., Chronic Hepatitis, in Harrison's Principles of INternal Medicine D.L. Longo, 
Fauci, A. S., Kasper, D. L., Hauser, S. L., Jameson, J. L., Loscalzo, J., Editor. 2011, McGraw-
Hill. p. 2567-2588. 
 
2. Dancygier, H., Viral Infections by Hepatotropic Viruses, in Clinical Hepatology: Principles and 
Practice of Hepatobiliary Diseases 2010, Springer: New York, NY. p. 771-780. 
 
3. Dienstag, J.L., Acute Viral Hepatitis, in Harrison's Principles of Internal Medicine, D.L. Longo, 
Fauci, A. S., Kasper, D. L., Hauser, S. L., Jameson, J. L., Loscalzo, J., Editor. 2011, Mc Graw 
Hill Medical. p. 2537-2557. 
 
4. McMahon, B.J., Natural history of chronic hepatitis B. Clin Liver Dis, 2010. 14(3): p. 381-96. 
 
5. Lok, A.S., The maze of treatments for hepatitis B. N Engl J Med, 2005. 352(26): p. 2743-6. 
 
6. Sherman, M., Predicting survival in hepatitis B. Gut, 2005. 54(11): p. 1521-3. 
 
7. Evans, A.A., et al., Eight-year follow-up of the 90,000-person Haimen City cohort: I. 
Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol 
Biomarkers Prev, 2002. 11(4): p. 369-76. 
 
8. Chen, G., et al., Past HBV viral load as predictor of mortality and morbidity from HCC and 
chronic liver disease in a prospective study. Am J Gastroenterol, 2006. 101(8): p. 1797-803. 
 
9. Wang, S.H., P.J. Chen, and S.H. Yeh, Gender Disparity in Chronic Hepatitis B: Mechanisms of 
Sex Hormones. J Gastroenterol Hepatol, 2015. 
 
10. Wang, S.H., et al., Identification of androgen response elements in the enhancer I of hepatitis B 
virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology, 2009. 50(5): p. 1392-
1402. 
 
11. Chiu, C.-M., et al., Hepatitis B virus X protein enhances androgen receptor-responsive gene 
expression depending on androgen level. Proceedings of the National Academy of Sciences, 
2007. 104(8): p. 2571-2578. 
 
12. Tian, Y., et al., Enhancement of hepatitis B virus replication by androgen and its receptor in 
mice. Journal of virology, 2012. 86(4): p. 1904-1910. 
 
13. Chen, C.J., et al., Risk of hepatocellular carcinoma across a biological gradient of serum 
hepatitis B virus DNA level. JAMA, 2006. 295(1): p. 65-73. 
 
14. Chu, C.J., M. Hussain, and A.S. Lok, Quantitative serum HBV DNA levels during different stages 
of chronic hepatitis B infection. Hepatology, 2002. 36(6): p. 1408-1415. 
 
15. McMahon, B.J., The natural history of chronic hepatitis B virus infection. Hepatology, 2009. 
49(5 Suppl): p. S45-55. 
 
16. Loeb, K.R., et al., High‐Throughput Quantitative Analysis of Hepatitis B Virus DNA in Serum 
Using the TaqMan Fluorogenic Detection System. Hepatology, 2000. 32(3): p. 626-629. 
 
 
98 
 
 
17. Tang, B., et al., Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma 
in chronic carriers. J Med Virol, 2004. 72(1): p. 35-40. 
 
18. Tran, T.T., et al., Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of 
Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials. PLoS One, 
2015. 10(3): p. e0121632. 
 
19. McMahon, B.J., Natural history of chronic hepatitis B - clinical implications. Medscape J Med, 
2008. 10(4): p. 91. 
 
20. Loizides, E., et al., Early response time in sexual activity and mood following testosterone gel 
replacement in hypogonadal males from the Testim® START study. Reviews in urology, 2004. 
6(Suppl 6): p. S16. 
 
21. Matsumoto, A.M., Andropause clinical implications of the decline in serum testosterone levels 
with aging in men. The Journals of Gerontology Series A: Biological Sciences and Medical 
Sciences, 2002. 57(2): p. M76-M99. 
 
22. Wang, S.H., et al., Estrogen receptor α represses transcription of HBV genes via interaction with 
hepatocyte nuclear factor 4α. Gastroenterology, 2012. 142(4): p. 989-998. e4. 
 
23. Missmer, S.A., et al., Endogenous estrogen, androgen, and progesterone concentrations and 
breast cancer risk among postmenopausal women. Journal of the National Cancer Institute, 2004. 
96(24): p. 1856-1865. 
 
24. McGlynn, K.A., et al., Reproductive factors, exogenous hormone use and risk of hepatocellular 
carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer, 2015. 
112 Suppl: p. 1266-72. 
 
25. Shimizu, I. and S. Ito, Protection of estrogens against the progression of chronic liver disease. 
Hepatol Res, 2007. 37(4): p. 239-47. 
 
26. Naugler, W.E., et al., Gender disparity in liver cancer due to sex differences in MyD88-dependent 
IL-6 production. Science, 2007. 317(5834): p. 121-4. 
 
27. Kakumu, S., et al., Serum interleukin 6 levels in patients with chronic hepatitis B. The American 
journal of gastroenterology, 1991. 86(12): p. 1804-1808. 
 
28. McMahon, B.J., et al., Serologic and clinical outcomes of 1536 Alaska Natives chronically 
infected with hepatitis B virus. Ann Intern Med, 2001. 135(9): p. 759-68. 
 
 
 
 
 
 
 
 
 
99 
 
Tables and figures 
Table 4-1. Basic characteristics and liver disease status among participants in Haimen City cohort 
in 2003   
Variable  Total  Liver status 
 (n = 1863) 
Normal  
(n = 1059) 
Abnormal 
(n=804) P-value 
Age  52.2±17.3 52.9±9.2 51.4±8.3 <0.01** 
Gender (%)     
Male 
1051 
(56.4) 512 (48.4) 539 (67.0) <0.01▲ 
Female 812 (43.6) 547 (51.7) 265 (33.0)  
Occupation (%)    0.36 ▲ 
       Peasant 1450 (77.8) 830 (78.4) 620 (77.1)  
        Non-peasant 413 (22.2) 229 (21.6) 184 (22.9)  
Putative immune 
status     
tolerant 48 (4.5) 48 (4.5) 0 <0.01▲ 
active/inactive 
1815 
(97.4) 1011 (95.5) 804 (100.0)   
HBeAg    <0.01▲ 
Positive 164 (8.8) 55 (5.2) 109 (13.6)  
Negative 
1699 
(91.2) 1004 (94.8) 695 (86.4)  
Log viral load in 
1993 5.3±1.9 4.9±1.7 5.8±2.1 <0.01** 
Undetectable log 
viral load<3.2 
(<1.6×103 
copies/mL) 314 (16.9) 201 (19.0) 113 (14.1) <0.01¶ 
Low viral load 
3.2≤log viral 
load<5 (<105 
copies/mL) 806 (43.3) 506 (47.8) 300 (37.3)  
High viral load 
log viral load≥5 
(≥105 copies/mL) 743 (39.9) 352 (33.2) 391 (48.6)  
Log viral load in 
2003 4.6±1.6 4.4±1.4 4.9±1.7 <0.01** 
Undetectable log 
viral load<3.2 
(<1.6×103 
copies/mL) 351 (18.8) 218 (20.6) 133 (16.5) <0.01¶ 
Low viral load 
3.2≤log viral 925 (49.7) 596 (56.3) 329 (40.9)  
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load<5 (<105 
copies/mL) 
High viral load 
log viral load≥5 
(≥105 copies/mL) 587(31.5) 245 (23.1) 342 (42.5)  
** T test  
* Wilcoxon rank test 
§ Fisher’s exact test 
▲ Chi-square test 
¶ Cochran-Armitage Trend test 
 
 
 
Table 4-2. Estimate HBV viral load change over time based on random mixed model. 
 Estimate Standard error P value 
intercept 5.7 0.19 <0.01 
Time -0.31 0.07 <0.01 
Male gender 1.1 0.15 <0.01 
Time*male 
gender 
-0.69 0.1 <0.01 
age -0.01 0.003 <0.01 
HBeAg positive 3.4 0.09 <0.01 
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Table 4-3. Association between hepatitis B viral load and liver disease severity 
Variables Crude 
ORs for 
abnormal 
liver status 
in 2003 
N=1863 
Adjusted ORs for 
abnormal liver status 
in 2003 (adjusted for 
age, HBeAg, and 
gender) 
N=1863 
Adjusted ORs 
for abnormal 
liver status in 
2003 in Women 
N=812 
Adjusted 
ORs for 
abnormal 
liver status 
in 2003 in 
Men 
N=1051 
Adjusted ORs 
for abnormal 
liver status in 
2003 in women 
with HBeAg 
negative 
N=755 
Adjusted 
ORs for 
abnormal 
liver status in 
2003 in Men 
with HBeAg 
negative 
N=944 
HBeAg positive in 2003 - 2.3 (1.9-2.9) 1.3 (0.70-2.6) 1.0 (0.59-
1.8) 
- - 
Menopause status in women - - 2.0 (1.3-3.2) - 1.8 (1.1-2.9) - 
age - 0.98 (0.97-0.99) 0.94 (0.91-0.97) 0.98 (0.97-
1.0) 
0.94 (0.91-
0.97) 
0.98 (0.97-
0.99) 
Log viral 
load in 2003 
Log viral 
load in 1993 
      
Undetectable 
(<1.6×103 
copies/mL) 
Undetectable 
(<1.6×103 
copies/mL) 
1 
(reference) 
1 (reference) 1 (reference) 1 
(reference) 
1 (reference) 1 (reference) 
 Low viral 
load(<105 
copies/mL) 
1.6 (0.83-
3.0) 
1.6 (0.84-3.1) 3.2 (0.66-15.5) 1.4 (0.66-
2.9) 
3.3 (0.67-15.9) 1.4 (0.65-
2.9) 
 High viral 
load (≥105 
copies/mL) 
1.6 (0.81-
3.1) 
1.7 (0.84-3.3) 3.8 (0.74-19.1) 1.3 (0.61-
3.0) 
3.6 (0.70-18.2) 1.3 (0.61-
3.0) 
Low viral 
load(<105 
copies/mL) 
Undetectable 
(<1.6×103 
copies/mL) 
1.2 (0.61-
2.2) 
1.5 (0.76-2.8) 2.7 (0.58-13.0) 1.4 (0.65-
3.1) 
2.7 (0.58-13.0) 1.4 (0.65-
3.2) 
 Low viral 
load(<105 
copies/mL) 
1.2 (0.66-
2.2) 
1.4 (0.76-2.6) 4.1 (0.90-18.4) 0.96 (0.48-
1.9) 
4.1 (0.91-18.4) 0.95 (0.47-
1.9) 
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 High viral 
load (≥105 
copies/mL) 
1.7 (0.92-
3.1) 
1.8 (0.97-3.4) 4.5 (0.97-20.7) 1.4 (0.69-
2.9) 
4.4 (0.95-20.2) 1.4 (0.67-
2.8) 
High viral 
load (≥105 
copies/mL) 
Undetectable 
(<1.6×103 
copies/mL) 
2.3 (1.1-
4.8) 
2.8 (1.4-6.0) 5.3 (1.0-26.5) 3.0 (1.2-7.7) 5.2 (1.0-26.7) 2.5 (0.91-
7.1) 
 Low viral 
load(<105 
copies/mL) 
2.0 (1.1-
3.9) 
2.6 (1.3-5.0) 5.2 (1.1-24.2) 2.4 (1.1-5.4) 5.2 (1.1-24.2) 2.4 (1.1-5.2) 
 High viral 
load (≥105 
copies/mL) 
4.8 (2.6-
8.8) 
5.1 (2.7-9.8) 10.4 (2.2-48.2) 4.7 (2.2-
10.1) 
10.8 (2.3-50.1) 5.6 (2.5-
12.2) 
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Figure 4-1. Mean hepatitis B viral load change over time by males and females 
 
 
 
 
 
 
 
 
 
 
  
Gender=0: men  
Gender=1: female 
The blue line indicated population mean. 
 
 
Figure 4-2. Predicted and observed probability of abnormal liver disease by hepatitis B viral 
load change between 1993 and 2003 in females.  
 
 
Virdif: log viral load difference between 1993 and 2003 (viral load1993-viral load2003) 
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Figure 4-3. Predicted and observed probability of abnormal liver disease by hepatitis B viral 
load change between 1993 and 2003 in males.  
 
Virdif: log viral load difference between 1993 and 2003 (viral load1993-viral load2003) 
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Appendices 
Appendix 4-1. Association between hepatitis B viral load and liver disease severity. 
Viral load in 
2003 
Viral load in 
1993 
ORs for normal 
liver  
ORs for mild liver 
disease  
ORs for moderate 
liver disease 
ORs for severe liver 
disease 
Undetectabl
e (<1.6×103 
copies/mL) 
Undetectable 
(<1.6×103 
copies/mL) 
1 (reference) 1 (reference) 1 (reference) 1 (reference) 
 Low viral 
load(<105 
copies/mL) 
1 (reference) 4.3 (0.53-34.1) 1.8 (0.70-4.7) 1.2 (0.52-2.6) 
 High viral load 
(≥105 copies/mL) 
1 (reference) 5.9 (0.72-47.5) 1.3 (0.45-3.6) 1.4 (0.61-3.2) 
Low viral 
load(<105 
copies/mL) 
Undetectable 
(<1.6×103 
copies/mL) 
1 (reference) 3.6 (0.45-29.1) 1.1 (0.4-2.9) 1.0 (0.47-2.3) 
 Low viral 
load(<105 
copies/mL) 
1 (reference) 3.8 (0.50-28.5) 1.0 (0.41-2.6) 1.1 (0.54-2.3) 
 High viral load 
(≥105 copies/mL) 
1 (reference) 5.6 (0.74-42.8) 0.99 (0.38-2.6) 1.7 (0.83-3.7) 
High viral 
load (≥105 
copies/mL) 
Undetectable 
(<1.6×103 
copies/mL) 
1 (reference) 11.7 (1.4-94.9) 0.94 (0.26-3.3) 2.2 (0.90-5.2) 
 Low viral 
load(<105 
copies/mL) 
1 (reference) 7.3 (0.94-57.3) 1.5 (0.58-4.1) 1.9 (0.87-4.1) 
 High viral load 
(≥105 copies/mL) 
1 (reference) 17.7 (2.3-134.0) 2.0 (0.74-5.32) 4.6 (2.1-9.7) 
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Appendix 4-2. Sensitivity analysis for association between hepatitis B viral load and liver disease severity. 
Variables Crude 
ORs for 
abnormal 
liver status 
e in 2003 
N=1815 
Adjusted ORs for 
abnormal liver status 
in 2003 (adjusted for 
age, HBeAg, and 
gender) 
N=1815 
Adjusted ORs 
for abnormal 
liver status in 
2003 in Women 
N=791 
Adjusted 
ORs for 
abnormal 
liver status 
in 2003 in 
Men 
N=1024 
Adjusted ORs 
for abnormal 
liver status in 
2003 in women 
with HBeAg 
negative 
N=755 
Adjusted 
ORs for 
abnormal 
liver status in 
2003 in Men 
with HBeAg 
negative 
N=944 
HBeAg positive in 2003 - 9.4 (4.2-21.0) 7.1 (2.6-19.8) 14.8 (3.5-
63.2) 
- - 
Menopause status in women - - 1.8 (1.1-2.9) - 1.8 (1.1-2.9) - 
age - 0.98 (0.96-0.99) 0.94 (0.91-0.97) 0.98 (0.97-
1.0) 
0.94 (0.91-
0.97) 
0.98 (0.97-
0.99) 
Log viral 
load in 2003 
Log viral 
load in 1993 
      
Undetectable 
(<1.6×103 
copies/mL) 
Undetectable 
(<1.6×103 
copies/mL) 
1 
(reference) 
1 (reference) 1 (reference) 1 
(reference) 
1 (reference) 1 (reference) 
 Low viral 
load(<105 
copies/mL) 
1.6 (0.83-
3.0) 
1.6 (0.83-3.1) 3.1 (0.63-15.0) 1.4 (0.65-
2.9) 
3.3 (0.67-15.9) 1.4 (0.65-
2.9) 
 High viral 
load (≥105 
copies/mL) 
1.6 (0.81-
3.1) 
1.6 (0.83-3.3) 3.6 (0.71-18.3) 1.3 (0.61-
3.0) 
3.6 (0.70-18.2) 1.3 (0.61-
3.0) 
Low viral 
load(<105 
copies/mL) 
Undetectable 
(<1.6×103 
copies/mL) 
1.2 (0.61-
2.2) 
1.5 (0.76-2.8) 2.7 (0.57-12.9) 1.4 (0.65-
3.1) 
2.7 (0.58-13.0) 1.4 (0.65-
3.2) 
 Low viral 
load(<105 
copies/mL) 
1.2 (0.66-
2.2) 
1.5 (0.76-2.9) 4.0 (0.90-18.2) 0.95 (0.47-
1.9) 
4.1 (0.91-18.4) 0.95 (0.47-
1.9) 
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 High viral 
load (≥105 
copies/mL) 
1.7 (0.92-
3.1) 
1.8 (0.95-3.3) 4.3 (0.93-19.8) 1.4 (0.68-
2.8) 
4.4 (0.95-20.2) 1.4 (0.67-
2.8) 
High viral 
load (≥105 
copies/mL) 
Undetectable 
(<1.6×103 
copies/mL) 
2.6 (1.3-
5.4) 
2.6 (1.2-5.6) 4.9 (0.95-24.8) 2.7 (0.97-
7.4) 
5.2 (1.0-26.7) 2.5 (0.91-
7.1) 
 Low viral 
load(<105 
copies/mL) 
2.0 (1.1-
3.9) 
2.6 (1.3-4.9) 5.1 (1.1-23.9) 2.4 (1.1-5.2) 5.2 (1.1-24.2) 2.4 (1.1-5.2) 
 High viral 
load (≥105 
copies/mL) 
7.8 (4.2-
14.6) 
5.8 (3.0-11.2) 11.3 (2.4-52.6) 5.4 (2.5-
11.8) 
10.8 (2.3-50.1) 5.6 (2.5-
12.2) 
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CHAPTER V. DISCUSSION 
5.1. Gender Disparities on Liver Disease Severity in Chronic Hepatitis B (CHB) Population 
      This dissertation aims to show the gender difference in liver disease severity among CHB 
patients and examine potential explanations of this difference. Based on the observations 
discussed in Chapter II, in HBeAg-negative participants, males were approximately 2.15 times as 
likely to have more severe liver disease compared to females, while in HBeAg positive 
participants, males were approximately 1.65 times as likely to have more severe liver disease 
compared to females.  
      In this dissertation, we tested three hypotheses that could potentially explain the gender 
difference between male and female liver disease severity in the hepatitis B infected population. 
We first tested the hypothesis that the gender difference in liver disease severity among CHB 
could be explained by life-style and environmental exposures. We next tested the hypothesis that 
female estrogen exposure, examined through the proxies of reproductive history and exogenous 
hormone use, could explain the different risk of liver disease severity in the female CHB 
population. Finally, we tested the hypothesis that gender difference of liver disease severity 
could be explained by the effect of sex hormones on HBV viral load.  
       In Chapter II, we discussed the effect of lifestyle and environmental exposures on the gender 
discrepancy in liver disease severity. We applied several statistical approaches to break down the 
lifestyle and environmental exposures in the population. However, adjustment for lifestyle and 
environmental exposure does not change the magnitude of the gender effect (the change of odds 
ratios were all less than 5%) on liver disease severity.  Some lifestyle and environmental 
exposure factors (smoking and alcohol consumption) have bivariate associations with gender or 
liver disease severity. We found that alcohol consumption was an independent risk factor for 
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liver disease severity. This finding is consistent with previous studies [1, 2]. Current or previous 
smoking was associated with increased odds of severe liver disease in this population, which was 
also consistent with previous studies [3, 4]. However, regarding the association between gender 
and liver disease severity in the CHB population, they are not confounding factors. Since the 
difference in lifestyle and environmental exposures between males and females does not explain 
the gender difference in liver disease severity among CHB, we then explored in chapters III and 
IV whether or not sex hormone are the key factor that drive this difference. 
      In Chapter III, we tested the impact of estrogen exposure in women by examining the effect 
of reproductive history on the severity of liver disease in CHB women. Our results showed that 
postmenopausal status is an independent risk factor for abnormal liver condition among CHB 
women. Postmenopausal women associated with 1.9 (95% CI 1.2-3.1) increased odds of having 
abnormal liver condition compare to those who are premenopausal. We also observed that 
menopausal status modified the association between HBeAg and liver disease in the hepatitis B 
infected population. The combined effect of postmenopausal status and HBeAg seropositive on 
liver disease is synergistic. HBeAg positive strongly associated with liver disease in 
postmenopausal women. Premenopausal women with HBeAg seropositive were associated with 
an approximately 7-fold increase in the likelihood of liver disease compared to premenopausal 
women with HBeAg seronegative, while postmenopausal women with HBeAg seropositive were 
associated with an approximately 60-fold increase in the likelihood of liver disease compared to 
those premenopausal women with HBeAg seronegative. Our findings are consistent with the 
hypothesis that estrogen exposure reduces the effect of hepatitis B viral replication on liver 
disease in CHB women. HBeAg seropositive is an important indication for HBV viral replication 
[5], and it has been associated with liver disease severity and the prognosis for the CHB 
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population in previous studies [6-8]. A previous study indicated that estrogen suppresses the 
liver’s innate immune response and has a protective effect on liver disease progression in CHB 
patients [9].  Liu, et al’s study provided evidence that estrogen receptor ERα expression was 
decreased among most female hepatocellular carcinoma patients [10]. Based on animal 
experiments, Naugler, et al proved that ERα plays a role in inhibiting Kupffer cells’ interleukin 6 
(IL-6) production in the liver and protects female mice against liver damage [11]. Since IL-6 
significantly increases when liver disease is exacerbated and during clearance of HBeAg [12], 
the evidence suggests that estrogen could play an important role in protecting females against 
inflammation-induced liver damage during the virus clearance process. 
      Our findings did not support the association between women’s parity status and liver disease. 
Although no previous studies have tested the association between parity status and liver disease 
severity among the CHB population, other studies’ findings regarding the association between 
parity status and the risk of liver cancer or liver disease in the general population were not 
consistent [13-15]. During the later stage of pregnancy, especially the third trimester, females 
will experience about 100 times the regular exposure of estrogen [16]. However, there is no 
substantial estrogen increase during the early stage of pregnancy [17]. Reproductive history, 
especially parity status, is a proxy measurement for lifetime estrogen exposure, but it only 
represents a short time and high dose of estrogen exposure. Based on our observation and the 
controversial results from previous studies on liver cancer [13-15], it might suggest that such 
measurements are unable to predict liver disease progression in the human population.    
      In Chapter IV, we examined HBV viral load change over time among men and women and 
determine how this change may predict later liver disease condition in the CHB population. 
Based on our observation, males often had higher viral loads at the beginning of the study 
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compared to females, but then dropped faster than females at the end of the study. The predicted 
decrease of log viral load over time for males is 0.77 and for females is 0.33 in 10 years’ time. 
Previous studies have also observed that older CHB patients have lower viral loads compared to 
younger patients [18].  CHB patients, especially those who were infected through perinatal 
transmission, often experience several decades in the immune tolerant phase [19, 20]. During this 
phase, patients would have high viral load and be HBeAg seropositive but have minimum liver 
damage [19, 20]. Most patients at later points of their life enter the immune active phase and the 
immune inactive phase. During the immune active or inactive phase, patients often develop anti-
HBe through adaptive immunity and start clearance of the HBV virus [19, 20]. This phenomenon 
could explain the HBV viral load decrease in the population. To our knowledge, the gender 
difference on the decrease of viral load over time has not been reported by previous studies. 
Tian, et al. have observed that androgen-stimulated androgen receptors (AR) increased HBV 
transcription [21]. They also identified two androgen response elements (ARE) located in HBV 
nucleotide (913-927 and 949-963) enhancer I. These ARE were available for binding in various 
HBV genotypes [21-23]. Therefore, high serum androgen in males could up-regulate HBV gene 
transcription and encourage high viral load in males [21-23]. Based on previous studies, men 
have been shown to experience androgen decrease over time [24, 25]. Our findings suggest that 
the decrease of endogenous androgen in males might decrease HBV transcription and is 
associated with a decreased viral load in males.  
      We observed that high viral load (≥105 copies/mL) in 2003 predicted increased odds of liver 
disease in this population. Previous published papers based on this population have noted that 
past viral load predicted liver disease mortality and hepatocellular carcinoma (HCC) [8]. Also, 
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previous studies done in other populations have suggested that viral load of ≥105 copies/mL is a 
predictor of high mortality from liver disease and HCC [8].        
5.2. Immune status in chronic hepatitis B study  
       In order to demonstrate the protective effect of estrogen exposure on liver damage, in 
Chapter III we excluded 24 female participants that were identified as putative immune tolerant. 
There are three major immune phases in the CHB population: the immune tolerant phases, 
immune active phase, and inactive hepatitis B phase [26, 27]. Immune tolerant is characterized 
by as HBeAg seropositive, normal alanine aminotransferase (ALT≤35 units per liter), high viral 
load (≥105 copies/mL), and no indication of liver disease except liver cancer. Most immune 
tolerant phase individuals were infected through perinatal transmission from HBeAg positive 
mothers. This phase could last for several years to decades [26, 28]. Since those who are in the 
immune tolerant phase will have minimal or no liver damage or inflammation, the mechanism of 
liver cancer in this group is different [26]. Although those who remain in the immune tolerant are 
less likely to develop liver inflammation due to the liver’s innate immune response, there are a 
small number of them who do develop liver cancer. Since the HBV polymerase gene could 
randomly integrate into human hepatocyte DNA, high HBV viral load over time could lead to 
HCC due to the accumulation of integration sites in the liver [26].  
       When patients change from the immune tolerant phase to immune active or inactive phase, it 
is irreversible. The immune active phase is defined by elevated ALT and elevated HBV viral 
load. Patients usually suffer active liver inflammation, with or without fibrosis [26, 28]. Those in 
the immune active phase could enter the immune inactive phase and revert back to immune 
active phase later in their life [26]. The immune inactive phase is defined by the presence of anti-
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HBe positive, normal ALT, low viral load, and liver inflammation or fibrosis could be absent or 
minimal and improve over time [26].  
      Table 5-1 presents the odds ratios of abnormal liver condition by gender, HBeAg positive, 
and viral load in the models that included or excluded those who were considered immune 
tolerant in this study. HBeAg positive associated with about 10-fold (OR: 9.6, 95% CI: 3.6-25.7) 
increase in the odds of abnormal liver condition in females when immune tolerant participants 
were excluded. However, this effect changes to an odds ratio of 1.8 (95% CI: 0.98-3.2) when we 
included those who are immune tolerant in the female population. The same situation was 
observed in the male population. The OR for HBeAg positive is 19.0 (95% CI: 4.6-79.6) when 
we excluded the immune tolerant group, but decreased to 1.3 (95% CI: 0.77-2.1) when we 
included the immune tolerant group in the male population. Because the immune tolerant 
participants were HBeAg positive and had no liver damage, including them could mask the 
effect of HBeAg positive and other risk factors on liver damage.   
      Current liver disease studies done in the CHB population often understate the difference 
between immune phases. In order to address the effect of estrogen suppression of the innate 
immune response to HBV virus and eventually protect females from liver disease progression 
among CHB participants, immune tolerant phases must be taken into account in the estimation. 
This was done in Chapter III. Those in the immune tolerant phase are unlikely to develop an 
innate immune response regardless of HBV virus activity. Although they have a chance to 
develop liver cancer, the mechanism is different from those who are in the immune active or 
inactive phases. Thus, we believe our observation in Chapter III is not applicable to the immune 
tolerant group.  
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5.3. Potential pathway diagram 
      Figure 5-1 presents the conceptual diagram that was tested in this dissertation. Our 
observation did not support the hypothesis that the gender difference in liver disease severity 
among CHB patients could be explained by lifestyle and environmental exposure difference 
among males and females (Chapter II, aim 1). Our observation supports the hypothesis that 
estrogen exposure suppresses the liver’s innate immune response in CHB infected women who 
are in the immune active or inactive phase (Chapter III, aim 2). As far as our knowledge, we are 
the first group to report that in a human population. In addition to estrogen’s protective effect 
among those who are in the immune active and inactive phases, our observation also supports the 
hypothesis that androgen exposure up regulates HBV viral load. The gender difference in the 
speed of viral load decrease over time might associates with the decrease of androgen by age 
among males (Chapter IV, aim 3). This finding does not differentiate by CHB immune phases 
based on our observation. 
5.4. Public Health Implication 
      Our findings could provide insights for disease management in CHB population. Based on 
our results, high HBV viral load and HBeAg positive are predictors for CHB population. Based 
on our observation, current high HBV viral load is a predictor for liver damage, especially in 
men. Among men and post-menopausal women, HBeAg positive predicts higher odds of severe 
liver disease compared those who are HBeAg negative. Primary care physicians should regularly 
monitor CHB patients’ HBV viral load and HBeAg status. Among males or postmenopausal 
women in CHB high viral load or HBeAg seropositive suggests further examination, such as 
abdominal ultrasounds, should be considered to identify the patient’s liver condition. 
Additionally, antiviral therapy should be considered among those who have high HBV viral load 
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and are HBeAg seropositive. Last but not least, although smoking and alcohol consumption does 
not explain the gender difference in liver disease, they are associated with increased odds of 
severe liver disease. Alcohol consumption and smoking should be avoided by those in the CHB 
population. 
5.5. Recommendation for Future study 
      Although we found menopausal status modifies the effect of HBV active replication and liver 
disease severity, it is only based on cross-sectional observation. Future studies done in a 
prospective study design should be considered to validate this finding. In Chapter IV, we found 
that the trend of decreased HBV viral load over time are different by gender. However, we only 
had two repeated measurements on the HBV viral load. Future studies employing a longitudinal 
study design with a shorter time interval and more time points should be used to confirm our 
finding. There are very few studies that have been done on the CHB population. Most of them 
had a small sample size and were limited by cross-sectional study design. Considering the health 
burden caused by hepatitis B infection, further studies on the CHB population should be 
encouraged. In addition, most hepatitis B studies were done on Asian populations. Hepatitis B 
genotypes have distinct geographic and ethnic distributions [29]. Each genotype has different 
characteristics and disease progression patterns [29], and studies that examine other racial groups 
should be considered. At last, future studies in viral activity and liver disease progression should 
consider the difference between immune phases when trying to predict liver disease severity. 
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Tables and figures 
Table 5-1. Logistic regression model of liver condition and risk factors based on participants’ 
immune status 
 Female 
without 
immune 
tolerant group 
Female with 
immune 
tolerant group 
Male without 
immune 
tolerant group 
Male with 
immune 
tolerant group 
age 0.97 (0.95-0.99) 0.97 (0.95-0.99) 0.98 (0.97-0.99) 0.98 (0.97-1.0) 
HBeAg positive 9.6 (3.6-25.7) 1.8 (0.98-3.2) 19.0 (4.6-79.6) 1.3 (0.77-2.1) 
Viral load low vs. 
undetectable 
1.3 (0.81-2.1) 1.3 (0.79-2.0) 0.90 (0.65-1.23) 0.91 (0.66-1.2) 
Viral load high 
vs. undetectable 
2.5 (1.5-4.0) 2.3 (1.4-3.8) 2.8 (1.9-4.1) 2.7 (1.8-4.0) 
 
 
 
 
Figure 5-1. Conceptual diagram for hepatitis B virus activity, sex hormone on liver disease 
progression among chronic hepatitis B population   
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PROFESSIONAL EXPERIENCES  
 
10/2013-present  Drexel University School of Public Health, Center for Hunger Free  
     Communities                                                               Philadelphia, PA 
                             Biostatistician, Research Assistant                                            
Facilitated study design for randomized control trial study, data analyst 
for existing data and on-going study projects, develop manuscripts for 
existing and on-going study projects.   
09/2012-present  Drexel University School of Public Health                 Philadelphia, PA 
                             Teaching Assistant 
                             Teaching assistant for Introduction to Biostatistics, Intermediate 
                             Biostatistics II, and Intermediate Epidemiology 
10/2009-02/2011 University of Wisconsin-La Crosse                                 La Crosse, WI  
                             Graduate Assistantship  
     Teaching assistant for Human Disease Control and Prevention, Sexual  
                              Education, Stress Management, Medical Terminology, Foundation of 
                              Public Health and School Health Education  
01/2010-07/2010  La Crosse County Health Department                          La Crosse, WI  
                             Graduate Intern  
                             Worked on building La Crosse County Influenza-Like Illness 
                             Syndrome Surveillance System. 
06/2007-06/2008 Zhanjiang Central People’s Hospital                      Guangdong, China 
                             Residency  
 
